Stockwinners Market Radar for December 02, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:24 EST Cathie Wood's ARK Investment buys 156K shares of Pinterest today

19:50 EST Mainz Biomed NV trading halted, news pending

18:08 EST Alight exec sells $2.0M in common stock - In a regulatory filing, Alight disclosed that its President Gregory Goff sold 250K shares of common stock on November 27th in a total transaction size of $2.0M.

17:58 EST Gold Resource provides update on operational and liquidity matters - Gold Resource announces an update to the operational and liquidity matters that were reported at the end of the third quarter. During the month of November, the company has seen an improvement in production at the Don David Gold Mine as compared to earlier in the fourth quarter. Strategic mine planning succeeded in providing sufficient mining faces, and issues with the filter press and mill have been addressed for the time being. The improved production during the month, combined with high metal prices and the favorable US dollar to peso exchange rate, allowed the mine to operate at slightly better than break-even cash flow during the month. While the company's available cash balance remains a concern, based on recent performance at the mine, the company currently expects that operations at DDGM could continue through at least the first quarter of 2025 without immediate capital infusions. The company still requires additional funding for mining equipment, mill upgrades and working capital to develop the Three Sisters and Splay 31 areas that will be the basis for future production at DDGM. Without additional capital, the company currently expects that DDGM will not be able to operate near break-even cash flow beyond the first quarter of 2025. If any significant unforeseen production or processing challenges were to materialize at DDGM, the company's ability to continue to operate DDGM in the near-term would be further jeopardized. Various financing and funding options are currently being evaluated by the company. The company has also identified an overpayment by DDGM of Mexico taxes in 2023 and has submitted a tax refund request for approximately $3.8M. This amount is expected to be refunded to the company in 2025, although the exact timing of payment is unpredictable.

17:34 EST Red Cat Chief Technology Officer, George Matus, to depart - George Matus, Red Cat's Chief Technology Officer, is departing the company and is taking the role of CTO at Vector. As the founder of Teal Drones, George has played a vital role in Red Cat's journey, including the recent production selection of its Black Widow drones for the U.S. Army's SRR Program. His innovative contributions have significantly advanced Red Cat's technology and product development. Chris Rill, currently Director of Partner Integration, will also transition to the role of President of Teal Drones, another Red Cat subsidiary.

17:25 EST Serina Therapeutics secures $10M financing - The company states: "Serina Therapeutics announced a $10M equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252, enabled by its proprietary POZ Platform(TM) drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025. Under the terms of the funding agreement, Serina will issue one million shares of common stock at $10 per share, a 120% premium to the closing price on November 26, 2024. The financing will be delivered in two tranches: the first $5.0M tranche was received November 27, 2024, and the second $5.0M tranche by January 31, 2025. Serina filed a Form 8-K with the SEC on December 2, 2024 that provides additional information regarding this transaction. SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) and enable greater on time, with reduced off time, in advanced Parkinson's patients. SER-252 leverages strategic partner Enable Injections' enFuse(TM) wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection without skin reactions."

17:20 EST Canopy Growth, Acreage Holdings provide update on acquisition closing timeline - Canopy Growth (CGC) and Acreage Holdings (ACRHF) announced that it is anticipated that Canopy USA will complete its acquisition of Acreage on or around December 9, subject to the satisfaction or waiver of closing conditions set out in the arrangement agreements. Canopy Growth and Acreage are party to an arrangement agreement dated April 18, 2019, as amended, relating to the proposed acquisition of all issued and outstanding Class E subordinate voting shares of Acreage pursuant to a plan of arrangement under the Business Corporations Act. The fixed share acquisition is anticipated to occur immediately after the acquisition of the Class D subordinate voting shares of Acreage pursuant to a plan of arrangement under the Business Corporations Act in accordance with the arrangement agreement dated October 24, 2022, as amended, among Canopy Growth, Acreage and Canopy USA. Upon the closing of the acquisitions, Canopy USA will own 100% of the issued and outstanding shares of Acreage. As previously announced by Acreage, if the price of the common shares of Canopy Growth on the Nasdaq does not go above $5.00 prior to closing of the acquisitions, holders of fixed shares will not receive any consideration in exchange for their fixed shares.

17:14 EST The Hanover raises quarterly dividend to 90c per share from 85c - The dividend is payable December 27, 2024, to shareholders of record at the close of business on December 13, 2024.

17:07 EST Elastic CTO sells $16.4M in common stock - In a regulatory filing, Elastic disclosed that its CTO Shay Banon sold 150K shares of common stock on November 27th in a total transaction size of $16.4M.

16:49 EST Dominion COO Diane Leopold to retire on June 1, 2025 - Dominion Energy announced that Diane Leopold, executive vice president and COO, will retire on June 1, 2025, after a 36-year career in the energy industry, the past 30 of which she has spent at Dominion Energy. Leopold will remain chief operating officer, executive vice president, and a key member of the company's leadership team until June 1. During this transitional period Leopold will begin to transfer utility and contracted energy responsibilities to Ed Baine, currently president-Dominion Energy Virginia, who will become president-Utility Operations and Dominion Energy Virginia, and Eric Carr, currently chief nuclear officer, who will become chief nuclear officer and president-Nuclear Operations and Contracted Energy. Keller Kissam, president-Dominion Energy South Carolina, will report to Baine in his new role. Leopold will retain operational oversight of all major construction projects including the Coastal Virginia Offshore Wind project and Charybdis, the first Jones Act-compliant turbine installation vessel in the U.S.

16:48 EST Oshkosh names Matthew Field as CFO, succeeding Michael Pack - Oshkosh (OSK) announced the appointment of Matthew Field as CFO, effective December 16. Field will succeed Michael Pack, who transitioned to president of the company's Vocational segment earlier this year. With over 20 years of leadership in the automotive and aerospace sectors, Field brings a strong track record in strategic financial stewardship to Oshkosh. He is currently serving as CFO of Joby Aviation (JOBY), where he was instrumental in guiding the company through its public listing in 2021.

16:44 EST Zscaler down 6% at $195.85 after Q1 results and updated guidance - Shares of Zscaler are down 6% or $12.66 at $195.85 after the company reported Q1 results, issued Q2 guidance and also updated its FY25 projections. The management also reiterated that "effective August 1, 2024, the beginning of the company's fiscal year ending July 31, 2025, we are using a long-term projected non-GAAP tax rate of 23% for the purpose of determining our non-GAAP net income and non-GAAP net income per share to provide better consistency across interim reporting periods in fiscal 2025 and beyond."

16:41 EST Jasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma - Jasper Therapeutics, announced that the first patient has been dosed in Jasper's Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The Efficacy and Safety of briquilimab In participANts with allergic asthma. The ETESIAN study is evaluating a single administration of subcutaneous briquilimab in patients with asthma. "Dosing of the first patient in our ETESIAN study in asthma is a significant milestone, marking our third clinical program evaluating briquilimab in an inflammatory disease driven by unwanted mast cell activity," said Edwin Tucker, M.D., Chief Medical Officer of Jasper...We look forward to providing enrollment updates as we progress through the study and anticipate reporting the initial data in the second half of 2025."..."As a potent and targeted c-Kit inhibitor, I believe briquilimab has the potential to overcome the safety issues that have limited development of other c-Kit inhibiting agents and, in turn, serve as an important treatment option for patients suffering from asthma. I look forward to enrolling patients into the ETESIAN study."

16:37 EST Shimmick awarded $45.4M contract to complete Murray Street Bridge project - Shimmick Construction announces that it has been awarded a $45.4M contract to complete extensive seismic retrofitting and improvements to the Murray Street Bridge at the Santa Cruz Small Craft Harbor. The project will improve the bridge's seismic resilience while enhancing accessibility for cyclists and pedestrians. "This project exemplifies Shimmick's commitment to delivering critical infrastructure that improves both public safety and connectivity and builds on our legacy of infrastructure improvements that serve communities for generations. We are looking forward to partnering with the City of Santa Cruz to complete this important project," said Ural Yal, CEO of Shimmick.

16:35 EST Black Hills natural gas utility receives approval for new rates in Iowa - Black Hills announced that its Iowa natural gas utility, Black Hills/Iowa Gas Utility Company doing business as Black Hills Energy, received approval from the Iowa Utilities Commission of a settlement agreement for new rates. The new rates are designed to recover approximately $100M of pipeline system investments since the utility's last general rate filing in 2021. "We are pleased to receive approval of a settlement that supports our commitment to our Iowa customers and communities to deliver safe and reliable natural gas service," said Linn Evans, president and CEO of Black Hills Corp. "Our investments made on behalf of our customers are essential to supporting continued resilience of our Iowa natural gas system." The approved black box settlement agreement will generate approximately $15M of new annual revenues based on a weighted average cost of capital of 7.21%. In January 2025, final approved rates will replace interim rates in place since May 11..

16:33 EST J.M. Smucker closes divestiture of Voortman brand to Second Nature Brands - The J.M. Smucker Co. announced the closing of the transaction to divest the Voortman business to Second Nature Brands. The company previously announced the signing of a definitive agreement for the transaction on October 22. The all-cash transaction is valued at approximately $305M, subject to a working capital adjustment, and reflects the company's continued commitment to optimizing its portfolio and reallocating resources to its core growth brands. The transaction includes all Voortman trademarks and the company's leased manufacturing facility in Burlington, Ontario, Canada. In addition, approximately 300 employees will transition with the business.

16:31 EST Crane to sell Engineered Materials segment to KPS Capital for $227M - Crane Company announced that it has entered into a definitive agreement to sell its Engineered Materials business to KPS Capital Partners, LP for $227M. Crane Company and KPS anticipate closing the transaction in the first quarter of fiscal year 2025 subject to customary closing conditions, including receipt of regulatory approvals. Max Mitchell, CEO, said, "This divestiture reflects yet another important step forward following the numerous actions we have taken over the last few years to simplify our portfolio and focus our resources on our two strategic growth platforms: Aerospace & Electronics and Process Flow Technologies. Those simplification actions have included the divestiture of non-core assets including Crane Supply and the defeasement of legacy liabilities in 2022, followed by our 2023 separation transaction. Since the separation, we have continued to invest in our strategic growth platforms organically, and further strengthened those businesses with four strategic acquisitions: Baum Lined Piping, Vian Enterprises, CryoWorks, and Technifab Products. We will continue to actively manage our portfolio to drive sustainable, profitable growth for all our stakeholders."

16:29 EST TransMedics falls 10% to $76.19 after new CFO, updated FY24 guidance

16:25 EST Madison Covered Call and Equity Strategy Fund trading resumes

16:24 EST Interparfums to develop Off-White fragrance, cosmetic products - Interparfum announced that its 72% owned French subsidiary, Interparfums SA, has obtained all Off-White brand names and registered trademarks for Class 3 fragrance and cosmetic products, subject to an existing license that expires on December 31, 2025, when Interparfums will begin commercial use of the fragrance brands. The two companies will build a long-term relationship to work in unison on strategies, category launches, and market initiatives. Founded in 2012, by the late designer Virgil Abloh, Off-White is known for itsstreetwear influences and approach to youth luxury.

16:23 EST Parsons announces inauguration for Riyadh Metro - Parsons announced that the official inauguration took place on November 27 for the $27B Riyadh Metro. Parsons is one of three consultants working as part of a Parsons-led joint venture known as the Riyadh Metro Transit Consultants, or RMTC, along with Egis and Systra, providing project and construction management on two of the Royal Commission for Riyadh City's Riyadh Metro contracts which Parsons has now successfully delivered.

16:20 EST Rayonier announces new $300M share repurchase authorization - Rayonier "announced that the Company's board of directors has approved a new $300 million share repurchase authorization. The new authorization replaces and supersedes the Company's existing $100 million share repurchase authorization. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The new repurchase program has no time limit and may be suspended for periods or discontinued at any time."

16:18 EST Lam Research issues statement on newly announced export regulations - The company said, "Today, the U.S. government announced additional measures to further restrict semiconductor technology exports to China. Our initial assessment is that the effect of the announced measures on Lam's business will be broadly consistent with our prior expectations. As a result, at this time we have no plans to update Lam's financial guidance for the December 2024 quarter as stated in our earnings press release on October 23, 2024."

16:17 EST Ingram Micro to reduce headcount by 850 associates - The company states: "Ingram Micro announced it is undertaking a series of restructuring initiatives that will reduce its headcount by approximately 850 associates by the end of the first quarter of 2025. These changes aim to enhance organizational efficiency and strengthen customer service capabilities to better position the company for long-term, sustainable growth. Consistent with the company's standard practices, Ingram Micro is committed to providing support to all associates impacted by these actions."

16:16 EST Regional Management announces $30M stock buyback - Regional Management Corp. announced a $30M stock repurchase program and growth expectations for 2025. "Having executed well throughout the economic cycle, we carry strong momentum and a healthy balance sheet into the new year, with significant funding for continued execution on our long-term growth strategy and the return of excess capital to shareholders," said Robert W. Beck, President and Chief Executive Officer of Regional Management Corp. "To that end and based on our consistently strong performance, liquidity profile, capital position, and confidence in our future, we are pleased to announce the authorization by our Board of Directors of a $30 million stock repurchase program. The program will enable us to be opportunistic in repurchasing our common stock at a time when we believe it to be undervalued." "In addition, we will allocate capital in 2025 to accelerate our portfolio growth," added Mr. Beck. "We expect our ending net receivables to grow by 10% to 12% in 2025, up from a roughly 6% growth rate in 2024. We are increasing our pace of growth due to our confidence in our credit performance, improving consumer health, and strengthening macroeconomic conditions, including lower inflation, real wage growth, low unemployment, and a large number of open jobs, particularly for our customer set. Our portfolio growth will ramp up over the course of next year, following seasonally low loan demand during the first quarter tax season."

16:14 EST General Motors to sell stake in Lansing battery cell plant to partner LG Energy - General Motors announced it has reached a non-binding agreement to sell its stake in the nearly completed Ultium Cells LLC battery cell plant in Lansing, Michigan to its joint venture partnerLG Energy Solution. The transaction is expected to close in the 2025 first quarter, subject to customary closing conditions."GM expects to recoup its investment in the facility. The transaction does not change GM's ownership interest in Ultium Cells LLC. GM will continue to leverage the Ultium Cells plants in Warren, Ohio and Spring Hill, Tennessee to meet growing demand for its electric vehicles.LG Energy Solution will have immediate access to the nearly completed Lansing facility to begin the installation of equipment.Ultium Cells Lansing currently has nearly 100 employees and remains on track to meet its previously announced employment commitments," GM stated. "Our EV profitability is rapidly improving thanks in part to our strategic decision to build battery cells in the U.S. with LG Energy Solution. It will be years before some of our competitors approach this level of performance. We believe we have the right cell and manufacturing capabilities in place to grow with the EV market in a capital efficient manner. When completed, this transaction will also help LG Energy Solution meet demand by leveraging capacity that's nearly ready to come online and it will make GM even more efficient," said Paul Jacobson, GM executive vice president and CFO.

16:09 EST TransMedics names Gerardo Hernandez as CFO, succeeding Stephen Gordon - TransMedics Group (TMDX) announced the appointment of Gerardo Hernandez as the company's CFO, effective December 2. In this role, Hernandez joins the TransMedics executive leadership team, succeeding Stephen Gordon. To enable a smooth transition, Gordon will remain a non-executive employee of the company until March 31, 2025, before serving as a non-employee senior advisor to the company focusing on national transplant stakeholder engagement until March 31, 2026. Hernandez most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals (ALNY), a biopharmaceutical company focused on RNAi therapeutics.

16:07 EST Portillo's names Tony Darden as COO - Portillo's (PTLO) announced the appointment of Tony Darden as COO. A seasoned industry leader with more than 30 years of experience with multi-unit restaurant concepts, Darden will play a pivotal role in enhancing operations as Portillo's accelerates its strategic nationwide expansion. He will begin work with the brand on December 9. Darden joins Portillo's from Jack in the Box (JACK), where he served as COO overseeing systemwide operations for more than 2,200 locations across 21 states.

16:05 EST Vaxart completes enrollment in Phase 2b study evaluating its COVID-19 pill - Vaxar announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator. "We are pleased to complete the enrollment of the sentinel cohort, an important milestone that reflects the collaboration of our entire team, as well as the trust and commitment of the participants and investigators involved," said Dr. James F. Cummings, Vaxart's Chief Medical Officer. "We look forward to DSMB and FDA review followed by the planned initiation of the Phase 2b trial's second portion. Our continued progress brings us closer to our goal of potentially demonstrating advantages of our mucosal technology against an approved mRNA vaccine." An independent Data and Safety Monitoring Board DSMB nd the U.S. Food and Drug Administration FDA will review 30-day safety data from the sentinel cohort. Upon favorable review by the DSMB and FDA, the study will progress after Biomedical Advanced Research and Development Authority BARDA approval to the second part of the trial by enrolling approximately 10,000 participants. The trial will strive to enroll participants in line with U.S. demographics, as well as including at least 25% over the age of 65. Funding for this award was received under Project NextGen, a $5 B initiative led by BARDA and the National Institute of Allergy and Infectious Diseases NIAID to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart's project award through the Rapid Response Partnership Vehicle RRPV is valued at up to $456M. This project has been funded with federal funds from the U.S. Department of Health and Human Services HHS ; Administration for Strategic Preparedness and Response ASPR ; BARDA, under Other Transaction OT number 75A50123D00005.

16:01 EST Volato announces new patent-pending technology for cryptocurrency mining - Volato Group "announces a new patent-pending technology that advances how aircraft generate revenue by repurposing underutilized aircraft resources for cryptocurrency mining. First filed in 2023, this innovation has already benefited from significant Bitcoin price appreciation, reinforcing its potential to turn aviation's untapped resources into valuable digital assets. By default, the system operates using excess electricity generated during normal flight operations, ensuring seamless integration with no additional costs or resource demands. However, the system is designed to dynamically scale up and utilize additional onboard electricity when spoiled capacity-such as unoccupied seats or unused cargo space-occurs. This flexibility allows operators to transform inefficiencies into valuable Bitcoin assets, maximizing revenue potential while maintaining operational integrity. At the heart of Volato's invention is its patented use of specialty mining hardware, optimized to achieve peak performance at high altitudes. By operating in the cool and energy-rich environment of cruising aircraft, the system delivers superior efficiency compared to ground-based mining setups. Aircraft operators can seamlessly integrate this technology into standard operations, turning inefficiencies into opportunities without impacting the aircraft's primary function. Volato's patent-pending system aligns with aviation's growing focus on sustainability. The revenue generated from Bitcoin mining can support the purchase of Sustainable Aviation Fuel or fund carbon offset programs, offering a pathway to enhance profitability while reducing environmental impact. This dual benefit positions Volato's technology as an attractive tool for forward-thinking aircraft operators".

15:37 EST Logistic Properties of The Americas trading resumes

15:32 EST Logistic Properties of The Americas trading halted, volatility trading pause

13:53 EST Tesla shares up 3%, or 10.73, to $355.89 in afternoon trading

13:23 EST Interactive Brokers reports November DARTs 74% higher than prior year - Interactive Brokers reported its Electronic Brokerage monthly performance metrics for November, with highlights for the month that included: 3.306M Daily Average Revenue Trades, 74% higher than prior year and 17% higher than prior month; Ending client equity of $575.9B, 42% higher than prior year and 7% higher than prior month; Ending client margin loan balances of $60.2B, 43% higher than prior year and 2% higher than prior month; Ending client credit balances of $118.8B, including $4.7B in insured bank deposit sweeps, 17% higher than prior year and 1% higher than prior month; 3.253M client accounts, 29% higher than prior year and 2% higher than prior month; 227 annualized average cleared DARTs per client account; Average commission per cleared Commissionable Order of $2.70 including exchange, clearing and regulatory fees.

13:20 EST H.B. Fuller announces divestiture of flooring business to Pacific Avenue Capital - H.B. Fuller Company announced that it will reorganize the building and construction segments of its portfolio. The reorganization includes the sale of the Flooring business as well as combining the company's Insulated Glass, Woodworking, and Composite segments, currently part of Engineering Adhesives, with its Roofing and Building Envelope and Infrastructure segments to form a newly named Global Business Unit: Building Adhesive Solutions, effective with the start of H.B. Fuller's 2025 fiscal year. BAS, as combined, generated approximately $850M in net revenue and approximately $130M in adjusted EBITDA in fiscal year 2024. H.B. Fuller also announced today that it has sold its Flooring business to Pacific Avenue Capital Partners. "This move is consistent with our strategy to drive our portfolio and capital allocation to the highest margin, fastest growing segments of the $80B global adhesives industry," says H.B. Fuller President and CEO Celeste Mastin. Proceeds from the sale are expected to be $80M, and the divestiture will result in a reduction in annual revenue of approximately $160M and adjusted EBITDA of approximately $15M going forward. The acquisition closed on Dec. 2, the second day of H.B. Fuller's 2025 fiscal year. H.B. Fuller was advised in the sale by Harris Williams.

12:39 EST Stellantis sees process to appoint new permanent CEO concluding within 1H25 - Stellantis said in a statement: "The process to appoint the new permanent Chief Executive Officer is well under way, managed by a Special Committee of the Board, and will be concluded within the first half of 2025. While the appointment of the new CEO is concluded the following organization is implemented with immediate effect. The Interim Executive Committee will be responsible for the direction and oversight of the Company on behalf of the Board of Directors. The IEC will be chaired by John ELKANN... Richard PALMER is appointed as Special Adviser to the Chairman and will attend the IEC to act as a sounding board for the leadership team."

12:36 EST Simon Property reports 6.4% portfolio traffic increase over Black Friday weekend - Simon Property Group said it saw a "remarkably strong start" to the holiday shopping season on Black Friday that continued throughout the weekend, including a 6.4% increase in year-over-year traffic at its centers across the country amid preliminary reports of surging sales from retailers. Waves of customers kicked off their holiday shopping season across Simon's portfolio of centers across the country. Year-over-year traffic was up 5.9% on Black Friday and grew throughout the weekend, including a 6.3% increase on Saturday and 8.2% on Sunday. Data is verified by traffic counters deployed at Simon centers. The growth was experienced across all of Simon's platforms with Malls up an impressive +7.1%. The strong initial Black Friday reports represent a continuation of growth and momentum for Simon, which has seen a steady increase in shopper traffic leading into the holiday season, the company said. "On Black Friday and throughout the weekend, we saw even more evidence of what we already knew: Malls are thriving," said David Simon, Chairman, Chief Executive Officer and President of Simon. "Popular brands throughout our portfolio reported double-digit sales increases over the weekend compared to last year. Coast to coast, we saw lines prior to opening and throughout the day at many of our centers across the country. Shoppers know that Simon centers are a one-stop shop for all of their holiday needs. But beyond that, our incredible shopping destinations are places where people across all generations can connect and make holiday memories. We look forward to a continued strong holiday season."

12:18 EST Tesla unveils app for Apple Watch - As part of the 2024 Tesla (TSLA) Holiday Update, the car maker unveiled an app for Apple Watch (AAPL), which allows users to use their Apple Watch as their phone key, as well as view battery charge, open the trunk, and turn on climate control. In addition, the company announced the ability to save and watch Dashcam and Sentry Mode clips directly from the Tesla app. Reference Link

12:00 EST Zeta Global rises 15.9% - Zeta Global is up 15.9%, or $3.40 to $24.70.

12:00 EST Joby Aviation falls -11.7% - Joby Aviation is down -11.7%, or -$1.05 to $7.90.

12:00 EST Vertical Aerospace falls -28.2% - Vertical Aerospace is down -28.2%, or -$2.85 to $7.25.

11:04 EST AB InBev invests $10M in Jacksonville brewery - Anheuser-Busch announced a new $10M investment in its Jacksonville brewery. Over the last 5 years, Anheuser-Busch has invested nearly $2B in its facilities across the country to help create and sustain jobs and drive economic prosperity in the communities where it operates and its employees call home.Key Highlights of the Investment: Facility upgrades to maintain industry-leading quality standards and maximize efficiency Updates to the critical manufacturing equipment that make beer production possible Upgrades to critical plant infrastructure at the brewery The Jacksonville brewery, a cornerstone of Anheuser-Busch's U.S. operations since 1969, has played a crucial role in the $490M capital investments the brewer has made in Florida to date. Anheuser-Busch operates more than 120 facilities across the country and, with its distributor partners, employs 65,000 hardworking Americans. As the nation's leading brewer, Anheuser-Busch has the unique ability to create U.S. jobs and drive economic prosperity at this scale.

10:48 EST United Bankshares receives final regulatory approval for Piedmont acquisition - United Bankshares has received all requisite regulatory approvals for its proposed merger with Piedmont Bancorp. This merger strengthens United's position in the Mid-Atlantic and Southeast. The combined organization will have more than $32 billion in assets and a network of over 240 locations across eight states and Washington, D.C., in some of the nation's most desirable banking markets. This transaction represents United's 34th acquisition. The respective boards of directors of United and Piedmont previously approved the merger agreement. In addition, the stockholders of Piedmont have approved the merger. Under the agreement, United will acquire 100% of the outstanding shares of Piedmont in exchange for common shares of United. The merger is expected to close in early 2025, subject to the satisfaction of customary closing conditions. At that time, Piedmont will merge into United, and The Piedmont Bank will merge into United Bank, with United and United Bank being the surviving entities. The former Piedmont offices will operate under the DBA United Bankshares in the State of Georgia. The operational conversion is anticipated to take place in late first quarter of 2025.

10:27 EST NTIA provides context around cooperative agreement with VeriSign - The National Telecommunications and Information Administration announced Friday some context around the renewal of NTIA's existing Cooperative Agreement with Verisign, the registry operator for the .com Top Level Domain and a key player in the Internet's infrastructure, especially given concerns about .com pricing. Verisign manages the .com registry-just as other organizations manage registries like .biz or .org - and serves as a wholesaler of .com domains. Registrars and domain name resellers in turn sell domain names directly to businesses and individuals. The Internet Corporation for Assigned Names and Numbers directly contracts with registries to operate Top Level Domains. ICANN maintains its own .com registry agreement with Verisign, which it renewed last week. "The security and stability of the Internet are paramount to our national interests. The provider of .com registry services handles more than 300 billion queries per day on average, in the face of numerous cyberthreats. Over the years, Verisign has demonstrated itself to be a responsible steward, consistently maintaining the reliability of .com. Their track record has enabled a robust Top Level Domain that millions of Americans and citizens worldwide depend on daily. At the same time, Verisign's role as the .com registry does offer it significant power over wholesale pricing. The Agreement currently caps those prices at approximately $10 per domain per year, and would allow a 7% increase four out of the next six years. NTIA recognizes concerns about current pricing and believes a reduction in .com prices would be in the best interest of the public. We also recognize that prices at both the wholesale level and downstream, including prices charged by resellers and substantial markups by warehousers, need to be addressed. That said, both parties must agree to any changes in order for the Cooperative Agreement to be amended. Over the past several months, NTIA and Verisign have engaged in serious conversations, but, despite our best efforts, we have been unable to agree how wholesale .com pricing should change. Per its terms, the Cooperative Agreement will automatically renew and take effect on November 30, with its current requirements and existing price constraints in place. Given the importance of the Cooperative Agreement for the stability of the DNS, and the fact that NTIA does not have authority to set .com domain prices, we believe the continuation of the Agreement is in the public interest. NTIA will continue to look at pricing considerations and engage in oversight of the Cooperative Agreement to ensure that the Agreement fulfills its purpose to serve the public. The current terms do not permit any increases in wholesale .com prices until September 1, 2026, and we note that, absent the Agreement, higher prices would be possible, including during this period. We also note that the Cooperative Agreement continues to restrict Verisign from vertical integration for .com, meaning Verisign is not permitted to operate as a registrar for .com domains, a restriction that is not standard for other registries. Finally, we note that the Cooperative Agreement continues to provide that it "is not intended to confer federal antitrust immunity on Verisign." Reference Link

10:01 EST DraftKings CEO says November was 'more typical month' - DraftKings co-founder and CEO Jason Robins, speaking at the 4th Annual Craig-Hallum Online Gaming Conference, says November was a more typical month, even a little on the positive side, notes that "yesterday was not." Says "kind of goes up and down, depending on the day."

10:00 EST Dana rises 14.9% - Dana is up 14.9%, or $1.49 to $11.49.

10:00 EST Stellantis falls -7.6% - Stellantis is down -7.6%, or -$1.00 to $12.20.

10:00 EST Archer Aviation falls -14.0% - Archer Aviation is down -14.0%, or -$1.34 to $8.23.

09:49 EST Dana rises 12.2% - Dana is up 12.2%, or $1.22 to $11.22.

09:48 EST SOS Limited rises 15.6% - SOS Limited is up 15.6%, or $1.93 to $14.33.

09:47 EST Stellantis falls -6.8% - Stellantis is down -6.8%, or -90c to $12.30.

09:47 EST Himalaya Shipping falls -8.2% - Himalaya Shipping is down -8.2%, or -51c to $5.70.

09:43 EST Integrated Wellness, Btab announce filing of registration statement on Form S-4 - Integrated Wellness Acquisition, a publicly traded special purpose acquisition company, and Btab Ecommerce Group, a global e-commerce and digital supply chain solutions provider, jointly announced the confidential submission of a draft registration statement on Form S-4 by IWAC Holding Company Inc., a newly created holding company organized under the laws of Delaware with the U.S. SEC. The Registration Statement relates to the proposed business combination between WEL and Btab, previously announced on May 31. The combined company will seek to be listed on one of the national exchanges. Completion of the proposed transaction is subject to regulatory approval, the approval of WEL's shareholders and other customary closing conditions.

09:40 EST Unusual Machines Inc trading halted, volatility trading pause

09:40 EST Supermicro jumps 14% after special committee finds no misconduct - The shares are up 14%, or $4.41, to $37.05 in morning trading.

09:37 EST iClick Interactive Asia trading resumes

09:32 EST iClick Interactive Asia trading halted, volatility trading pause

09:30 EST NCS Multistage trading halted, volatility trading pause

09:28 EST Movano Health receives FDA clearance for EvieMED ring - Movano Health announced U.S. Food and Drug Administration, FDA, 510(k) clearance for the pulse oximeter in its EvieMED Ring. The clearance enables Movano Health to pursue multi-billion dollar business opportunities for health monitoring solutions needed for applications such as clinical trials, post-clinical trial management, and remote patient monitoring for both healthcare providers and payors.

09:27 EST Nisun International announces a $82M corn supply agreement - Nisun International announced a significant expansion into the agricultural supply chain with a strategic cooperation agreement with Henan Yingda Feng Agricultural Development. The agreement, which involves the annual supply of 200,000 tons of corn products, is valued at approximately RMB 600 Million, approximately $82 million USD.

09:25 EST Supermicro began process to search for new Chief Financial Officer - Supermicro announced that the independent special committee formed by the company's board of directors has completed its review. As a result of these findings, the Special Committee recommended that the company a number of measures to strengthen the company's governance and support the dynamic growth of the business operations: including transition to a new Chief Financial Officer; Appoint a Chief Accounting Officer; Appoint a Chief Compliance Officer; Appoint a General Counsel and Expand the Legal Department; and others. The board has adopted all of the Special Committee's recommendations. To address the Special Committee's recommendations, and being mindful of the company's rapid business growth over the past two years, the board has instructed management to add additional experienced, senior talent commensurate with the company's size and complexity today and to prepare for its future growth. Specifically, the board's action in adopting all of the Special Committee's recommendations includes the following updates and planned measures: The company has begun a process to search for a new Chief Financial Officer. David Weigand will continue to serve as the Company's CFO until the Board has named his successor. Additionally, the company is accelerating its search for a Chief Compliance Officer and for a General Counsel. Kenneth Cheung has been appointed Chief Accounting Officer. Mr. Cheung is currently the Vice President of Finance and Corporate Controller of Supermicro and previously served as the Vice President of Operations at the Company. The company will continue expanding and enhancing its training programs as part of its commitment to continuous improvements in its financial controls and compliance processes.

09:24 EST IGC Pharma expands clinical research program for IGC-AD1 - IGC Pharma announced an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy. The expanded research will explore how IGC-AD1's dual-action mechanism-combining anti-neuroinflammatory properties with amyloid- and tau-targeting effects-may slow the progression of Alzheimer's disease. These trials will evaluate critical outcomes, including cognitive function and biological markers associated with Alzheimer's, such as amyloid and tau levels, at multiple time points. Building on previously announced preclinical data showing IGC-AD1's impact on amyloid plaques and spatial memory, these investigations aim to explore its potential to influence key pathological features of Alzheimer's disease. As previously reported, preclinical studies in Alzheimer's mouse models demonstrated an approximate 50% improvement in spatial memory, and cell line data showed a significant 20% reduction in amyloid aggregation following treatment. These preclinical findings, along with the interim Phase 2 data on cognition, provide a solid scientific basis for the expanded research program, which aims to validate IGC-AD1's ability to address key pathological features of Alzheimer's disease. The ongoing 146-patient Phase 2 trial continues to enroll participants across the USA and Canada. With over 1,000 doses administered and no serious adverse events reported, the trial is on track to deliver comprehensive safety and efficacy data in 2025.

09:23 EST EON Resources announces $22.5M funding LOI with Enstream - EON Resources announced the signing of a non-binding Letter of Intent with Enstream Capital Management for $22.5 million of well completion funding. The Company anticipates using the WCF for the development of 45 wells using low-cost workovers on the Company's 13,700 leasehold acres in Eddy County, New Mexico. The Company also plans to use the funds for the acquisition of an Overriding Royalty Interest in the Property. The Company looks for key attributes of the WCF to include: Structured similar to a term overriding royalty interest to ECM and is considered neither debt nor equity. Provides asset-level funding to the Company enabling conversion of oil and gas "behind pipe" and lower-risk, proved undeveloped reserves into production. Placement of revenue attributable to ECM's interest into an escrow, then drawn monthly by the Company based upon, and to be used for, an agreed development plan under certain criteria. Increases the Company's producing reserves, business profitability, bank collateral and value, and balance sheet strength without diluting Company equity. EON and ECM view their relationship as a long-term opportunity to provide funding for multi-phase and multi-year development of the Property with minimal capital outlays by the Company. The details of the proposed production sharing arrangement proposed with ECM are confidential presently, but the Company's objectives will be to cause improvements in production, increase revenues, net cash flow and recoverable reserves over the next 12 months, with a goal to increase gross oil production by 1000 BOPD to 2000 BOPD. EON has substantial development prospects to pursue follow-on identified development phases, with over one billion barrels of original oil in place under its 13,700 contiguous acreage and 549 wells on its leases.

09:21 EST Nitches, Inc. announcs enhancements to InTheZone Labs - Nitches announced significant advancements within its subsidiary. These developments include the launch of a dedicated YouTube channel featuring in-depth, podcast-style product videos, ingredients based deep dives, and the expansion of affiliate marketing creative through and for affiliate programs like ShareASale and Awin networks. Recognizing the growing consumer preference for video content, InTheZone Labs has introduced a YouTube channel that offers comprehensive discussions on each product. These podcast-style videos are also embedded on the InTheZone Labs Products Page, providing potential customers with detailed insights into product benefits and applications. The videos are embedded on the products page but also easily accessible on YouTube as well. InTheZone Labs is actively enhancing its affiliate marketing efforts by partnering with leading networks such as ShareASale and Awin. New affiliates are encouraged to join the program to promote InTheZone's products, with a suite of marketing materials being developed to support their efforts. This initiative aligns with the company's commitment to "Get In The Zone for 2025," aiming to broaden product reach and consumer engagement. The company is undertaking continuous updates to its website and social media platforms to improve user experience and provide timely information. These enhancements are part of a broader strategy to keep stakeholders informed about product developments and company news. New photography, videography and marketing updates are happening daily for our push to get people to Get InTheZone for 2025. InTheZone Labs is preparing to release detailed results from its Phase One Testing in the beginning of December . These findings are expected to provide valuable insights into product efficacy and consumer satisfaction, reinforcing the company's dedication to transparency and quality. Our different key groups have been giving some preliminary updates that have been favorable. Our team is currently working with the team leads to get the science articulated right.

09:19 EST Bowlero rebrands as Lucky Strike Entertainment - Bowlero announced it will be rebranding to Lucky Strike Entertainment, effective December 12. As a part of this rebrand, Bowlero Corporation will also change its legal name to Lucky Strike Entertainment Corporation and its stock ticker symbol from (BOWL) to (LUCK), further emphasizing the brand's evolution. Following a rebranding initiative led by Kingsland. Key milestones in the rebrand include the transformation of over 75 Bowlero centers into Lucky Strike locations within the next two years, beginning with locations in high-profile markets such as Bowlero Chelsea Piers in Manhattan and Bowlero Tysons Corner in the DC area. This rollout will be highlighted by the debut of flagship locations, including Lucky Strike Beverly Hills in December.

09:15 EST Silynxcom introduces APC headset to enhance drone sound awareness - Silynxcom announced its product aimed at boosting situational awareness and safety for armored personnel carrier crews and other heavy military vehicles. This technology addresses a critical challenge on the modern battlefield: detecting the distinct and potentially life-threatening drone humming while simultaneously maintaining hearing protection in high-noise environments. Military crews operating within armored vehicles rely on specialized headsets to communicate effectively amidst the overwhelming noise generated by vehicle engines and live weaponry. These headsets facilitate internal and external communication. Current technology utilizes ANR. This technology employed in headsets, customarily used in civilian environments, such as commercial airliners or trains, can reduce repetitive noises, such as the APC vehicle engine. As the battlefield evolves, this characteristic of ANR headsets may lead to the blocking of certain sounds that ought to be detected, such as the faint buzz of an approaching drone, a sound that could signal an imminent threat. Silynxcom's new APC headset integrates advanced auditory technology to allow for hearing protection from continuous and sudden sounds, while facilitating the selective amplification of certain environmental sounds, such as drone noise. The new headset is compatible with the most popular APC intercom and radio systems, such as plug and play, allowing for seamless upgrade of existing systems.

09:13 EST Triller to initiate initial phase of 'rejuvenating' application in Q1 - Triller Group revealed a milestone in its evolution by introducing the latest iteration of Triller. The app is poised to transform the digital realm for content creators, enthusiasts, and businesses. Following the recent announcement of Sean Kim, former Head of Product at TikTok, as the new CEO of Triller App and the Company's Triller Platform Co. subsidiary, the company is committed to initiating the initial phase of rejuvenating its application in the first quarter of 2025. A Comprehensive App Roadmap: The next generation of Triller App is anchored by a three-phased roadmap aimed at maximizing the potential of the platform: Phase 1: Reignition: Triller Group will revamp our app discovery experience and content ecosystem with exclusive content from top creators. Phase 2: Empower Creator Ownership: Aligning with our mission, Triller Group aims to redefine industry standards by offering innovative ways for creations to get full control and ownership of their fan relationships. Phase 3: Monetization: Triller Group will launch new monetization opportunities for creators and brands with cutting-edge AI. Furthermore, they will have access to advanced marketing and analytics tools from Amplify.ai, Julius, and Fangage to fuel audience growth, engagement, and conversion. The first phase of the app is on track to launch in Q1 2025, representing a pivotal milestone in the app's journey toward delivering exclusive content and experiences.

09:11 EST Fortinet becomes Preferred Partner for Vancouver Canucks - NHL Vancouver Canucks and Fortinet announced that Fortinet has become the new Preferred Partner for the 2024-2025 season. Canucks Sports & Entertainment has chosen Fortinet's Security Fabric platform to reduce complexity and streamline the identification and remediation of network and security issues across the group's facilities.

09:10 EST Kulicke & Soffa completes $800M share repurchase program - Kulicke and Soffa Industries announced that it has completed its $800 million share repurchase program, originally initiated during its fiscal fourth quarter of 2017. Under this program, K&S repurchased approximately 22.7 million shares at an average price of approximately $35.25 per share. The completion of the program demonstrates the Company's commitment to its long-term growth prospects and delivering value directly to shareholders.

09:09 EST Lucas GC receives invention patent in AI in China - Lucas GC had received an invention patent "Talent Scout-Based Holistic Recruitment System" in China. This is the third patent that Lucas has obtained in the year of 2024, making the total numbers of patents that Lucas holds at nineteen. This patent enables social media influencers to reach out to targeted talents by matching personalized recruitment contents generated based on the job requirements and the profiles and behaviors of the potential candidates.

09:09 EST Castor Maritime announces sale of M/V Ariana A for $16.5M - Castor Maritime entered, through a separate wholly-owned subsidiary, into an agreement with an unaffiliated third party for the sale of the M/V Ariana A, a 2005-built 2,700 TEU containership vessel, for a price of $16.5 million. The vessel is expected to be delivered to its new owner during the first quarter of 2025. The Company expects to record during the first quarter of 2025 a net loss of approximately $3.3 million from the sale of the M/V Ariana A, excluding any transaction-related costs.

09:07 EST 180 Degree Capital notes average discount of NAV per share to stock price - 180 Degree Capital noted that the average discount between its estimated daily net asset value per share and its daily closing stock price during November 2024 and year-to-date through the end of November 2024, were approximately 21% and 20%, respectively. This discount was approximately 26% on November 29, 2024, the last day of trading of the month. As previously disclosed in a press release on November 13, 2023, 180 Degree Capital's Board of Directors has set two measurement periods of January 1, 2024 to December 31, 2024, and January 1, 2025 to June 30, 2025, in which it will evaluate the average discount between TURN's estimated daily NAV and its closing stock price pursuant to a Discount Management Program. Should TURN's common stock trade at an average daily discount to NAV of more than 12% during either of these measurement periods, the Board will consider all available options at the end of each measurement period including, but not limited to, a significant expansion of 180 Degree Capital's current stock buyback program of up to $5 million, cash distributions reflecting a return of capital to shareholders, a tender offer, or other strategic options.

09:05 EST Skyhawk adds Interactive Cloud Threat Detection, Response to platform - Skyhawk Security is adding an Interactive Cloud Threat Detection and Response capability to its platform. The new capability adds real-time user interaction to verify suspicious activity of both human and non-human identities that are the root cause of an alert. This closes context gaps between SOCs, cloud teams and identity owners, which reduces the load on the SOC, dramatically shortens Mean Time to Respond, better protects against cloud breaches and aligns with zero trust frameworks.

09:02 EST LPL Financial appoints Renana Friedlich as CISO - LPL Financial announced the strategic hire of Renana Friedlich as executive vice president and chief information security officer, bolstering the firm's commitment to cybersecurity in an increasingly challenging business landscape. Friedlich will report to Greg Gates, managing director and chief technology and information officer. In her new role, Friedlich will spearhead LPL's cybersecurity strategy and oversee the protection of the firm's IT infrastructure, networks and data. Before joining LPL, she was deputy CISO and senior director of cyber threat management at PayPal, leading a team of 120 security professionals

08:59 EST FDA finishes review of Delcath's IND application of HEPZATO combo trial - Delcath Systems announced that the U.S. Food and Drug Administration FDA has completed its 30-day review of the Company's Investigational New Drug IND application for a Phase 2 clinical trial evaluating HEPZATO in combination with standard of care SOC for liver-dominant metastatic colorectal cancer mCRC . With the FDA's review complete, Delcath is now authorized to initiate patient enrollment. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with trifluridine-tipiracil and bevacizumab compared to trifluridine-tipiracil and bevacizumab alone in patients with liver-dominant mCRC receiving third-line treatment. The trial's primary endpoint, hepatic progression-free survival hPFS , is anticipated to read out by the end of 2027, while overall survival OS , a secondary endpoint, is expected in 2028. "This Phase 2 trial represents an exciting step forward in evaluating HEPZATO as a treatment for patients with liver-dominant metastatic colorectal cancer," said Gerard Michel, Chief Executive Officer of Delcath Systems, Inc. "The study reflects our commitment to expand the potential applications of HEPZATO beyond metastatic uveal melanoma, offering new hope to an additional group of patients with liver dominant cancers."

08:54 EST Stereotaxis to showcase GenesisX Robotic System at RSNA 2024 - Stereotaxis and Neusoft Medical Systems announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's 2024 Annual Meeting taking place December 1-5 in Chicago, IL. RSNA is the premier annual radiology forum in the world, with over 50,000 attendees from over 150 countries. Neusoft Medical Systems is a global leader in advanced medical imaging solutions, with over 47,000 installed systems that provide high-quality care to patients and healthcare providers globally. Stereotaxis' GenesisX System, the latest innovation in endovascular robotics, is being showcased for the first time alongside Neusoft Medical Systems' NeuAngio 30F fluoroscopy system. Presence at RSNA reflects a growing collaboration between Stereotaxis and Neusoft Medical Systems to integrate and commercialize complementary technologies. GenesisX builds upon the well-established benefits of Robotic Magnetic Navigation technology, while reducing complexities and barriers to hospital adoption. This system is designed to enhance precision, efficiency, and safety across a broad range of endovascular procedures.

08:53 EST Kandi Technologies appoints Bin Yu as CEO, SC Autosports - Kandi Technologies Group announced that, following a thorough review and decision by its management team, Mr. Bin Yu has been appointed CEO of SC Autosports, the Company's U.S. subsidiary. Before joining Kandi, Mr. Yu held the following key positions: October 2020 - February 2024: Vice President, BoulderAI Technologies Co., Ltd., Hangzhou, China. Concurrently, Johnny Tai will transition from his role as CEO of SC Autosports to Vice President, where he will focus on expanding the Company's dealer network.

08:52 EST Alpha Modus, CashXAi to enter strategic partnership agreement - Alpha Modus Corp. and CashXAI announced a definitive agreement to enter a strategic partnership to grow the market share of CashX kiosks and wallet app infused with AI technology targeting retail consumer marketing. The partnership terms outline Alpha Modus and CashX will engage in joint marketing efforts to launch the kiosk solution in agreed target markets to create any necessary agreements and licenses to enable retailers and consumers to utilize the solution. The economic terms agreed upon by each company will determine shared revenues derived from the sale and use of the CashX kiosks and wallet app. Alpha Modus is party to a business combination agreement with Insight Acquisition Corp. whereby Alpha Modus plans to become a publicly trading company.

08:51 EST China Medical System gains exclusive commercialization right of ABP-671 - China Medical System entered into an Exclusive Commercialization Agreement with Atom Therapeutics of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia. In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China. Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement. ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1. The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat. The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia. Multiple patents in regard to substance and use of the ABP-671 have been granted in China. ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS's product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group's strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group's marketed product Metoject in rheumatology and with Elcitonin in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.

08:48 EST Spectral AI completes truthing of burn center images, initiaties image review - Spectral AI announced the completion of truthing for all images gathered from burn centers across the United States. This milestone represents a pivotal step in training the Company's proprietary DeepView System to predict wound healing outcomes accurately. Having completed the process for burn centers, Spectral AI is now initiating truthing for images collected from emergency departments and emergency rooms nationwide, expanding the scope of the DeepView System's capabilities. Truthing is the rigorous process of gathering 'ground truth' data that verifies whether portions of a wound did or did not heal and then using this data for training of its AI-powered algorithm. For each patient, images are collected during the early stages of treatment and correlated with biopsies, 21-day wound assessments, and expert evaluations. This combination of data creates a "ground truth" dataset, enabling the DeepView System to distinguish between wounds likely to heal and those requiring intervention. The Company's Burn Biopsy Algorithm, developed alongside leading experts, integrates advanced machine learning with clinical insights, allowing the DeepView System to identify healing trajectories with unprecedented effectiveness. By leveraging data from the largest burn tissue bank ever assembled, the DeepView System is designed to provide clinicians with actionable information and reducing guesswork. Now, Spectral AI is expanding its focus to emergency departments, where the stakes are equally high. The truthing process will include data collected during the critical early stages of care, enabling the DeepView System to adapt to a broader range of clinical scenarios.

08:46 EST Gelteq announces largest U.S. customer increases initial order by 50% - Gelteq announces its largest U.S. customer, Healthy Extracts, has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts' platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market. This growing partnership supports Gelteq's strategic push into the U.S. market following the recent hiring of Adam Bendell as the Company's U.S. President and the establishment of a U.S.-based office. Production of Healthy Extracts' order is underway, with shipment expected in January 2025. Gelteq and the Healthy Extracts team will continue to expand the range of their partnership and expect to announce new products in early 2025.

08:45 EST Eos Energy names Francis Richey as Chief Technology Officer - Eos Energy Enterprises "announced that Francis Richey, former Senior Vice President of Eos Research & Development, has been appointed Chief Technology Officer. Richey, who has been with Eos since 2015, brings a wealth of experience in electrochemical engineering and battery product development. Richey joined Eos as a Senior Battery Scientist in 2015 and quickly advanced through several leadership roles. Most recently he served as Senior Vice President of Eos Research and Development, where he played a pivotal role in the development of the Eos Z3(TM) battery and the advancement of the Company's energy storage technology."

08:42 EST Ready Capital enters merger agreement with United Development Funding IV - Ready Capital and United Development Funding IV announced that they have entered into a definitive merger agreement pursuant to which Ready Capital will acquire UDF IV. Upon completion of the transaction, Ready Capital is anticipated to have a pro forma equity capital base in excess of $2.2 billion. Under the terms of the merger agreement, UDF IV will be permitted to distribute up to $75 million of cash on its pre-closing balance sheet to its shareholders prior to the transaction closing representing value distributed by UDF IV to its shareholders of up to $2.44 per share. Following such distribution, as part of the merger consideration, each share of UDF IV common stock will then be converted into 0.416 shares of Ready Capital common stock, with UDF IV shareholders receiving a total of approximately 12.8 million shares of Ready Capital common stock. The Exchange Ratio was negotiated to reflect an adjustment for the expected Pre-Closing Distribution, as well as other valuation adjustments. Based on Ready Capital's closing share price on November 29, 2024, the implied value of the Ready Capital shares expected to be issued in connection with this closing is approximately $94 million or $3.07 per UDF IV share. At closing, UDF IV shareholders are expected to own approximately 7% of Ready Capital's outstanding shares. In addition, as part of the merger consideration, UDF IV shareholders will be entitled to receive additional stock consideration after closing under contingent value rights to be issued by Ready Capital, which UDF IV management estimates will generate payments of up to $0.38 per UDF IV share over time before any accrued dividends related to such Ready Capital shares are paid. The combined company will continue to operate under the name Ready Capital and its shares are expected to continue trading on the New York Stock Exchange under the existing ticker symbol "RC" and Waterfall Asset Management, LLC will continue to manage the combined company. Upon completion of the merger, Ready Capital's Chairman, Chief Executive Officer and Chief Investment Officer, Thomas Capasse, will continue to lead the company and Ready Capital executives Jack Ross, Andrew Ahlborn, Gary Taylor and Adam Zausmer will remain in their current roles. The combined company will remain headquartered in New York, New York. Under the terms of the CVR, UDF IV shareholders will have the right to receive additional shares of Ready Capital common stock with a value equal to 60% of any cash received from certain UDF IV loans in excess of the outstanding principal of such loans and net of certain costs. CVR holders will also receive consideration, payable at Ready Capital's option, in cash or additional Ready Capital shares, equal to the dividends paid on the Ready Capital shares issued under the CVRs during the period between the closing date and the share issuance date. The Trust estimates that UDF shareholders will receive approximately $0.38 in value per share from the CVR over time before accounting for any accrued dividends related to the Ready Capital shares issued. The transaction has been unanimously approved by the Board of Directors of Ready Capital and the Board of Trustees of UDF IV, acting upon the unanimous recommendation of a special committee of UDF IV's independent trustees. The transaction is expected to close in the first half of 2025, subject to the approval of UDF IV shareholders and other customary closing conditions.

08:38 EST Cematrix appoints Randy Boomhour as president, CEO - CEMATRIX announces that as part of the Company's succession plan, Randy Boomhour has been named President and CEO for the Corporation effective November 29, 2024. Mr. Boomhour joined CEMATRIX in 2020 as CFO, added the role of GM for CEMATRIX Canada in 2023, and was promoted to COO in 2024. Mr. Boomhour brings over 20 years of senior executive experience to his new role.

08:37 EST Cematrix CEO Jeff Kendrick to retire - CEMATRIX announces the retirement of Mr. Jeff Kendrick, President and CEO, effective November 29, 2024. Mr. Kendrick has also retired from the Board of Directors of the Company effective November 29, 2024. Mr. Kendrick has chosen to retire for personal and family reasons.

08:37 EST Intel up 6% after announcing retirement of CEO Pat Gelsinger - Shares of Intel are up $1.40, or 6%, to $25.45 in pre-market trading after the company announced that CEO Pat Gelsinger retired from the company and has stepped down from the board of directors, effective yesterday, December 1. Intel has named David Zinsner and Michelle Johnston Holthaus as interim Co-Chief Executive Officers while the board of directors conducts a search for a new CEO, it noted.

08:36 EST Psychemedics announces reverse stock split, forward stock split - Psychemedics announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock followed immediately by a 5,000-for-1 forward stock split of its common stock, to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 2024. Beginning with the opening of trading on Wednesday, December 4, 2024, the Company's common stock will continue to trade on the Nasdaq Capital Market on a post-Forward Stock Split basis under the existing symbol "PMD". Stockholders who hold fewer than 5,000 shares immediately prior to the Reverse Stock Split will be paid $2.35 in cash, without interest, for each share of the Company's common stock held by them at the effective time of the Reverse Stock Split, and thereafter they will no longer be stockholders of the Company. Stockholders owning more than 5,000 shares of the Company's common stock at the effective time of the Reverse Stock Split will not be entitled to receive any cash for their fractional share interests resulting from the Reverse Stock Split, if any. The Forward Stock Split, which will immediately follow the Reverse Stock Split, will reconvert whole shares and fractional share interests held by the Continuing Stockholders back into the same number of shares of common stock held by such Continuing Stockholders immediately before the effective time of the Reverse Stock Split. As a result of the Forward Stock Split, the total number of shares of the Company's common stock held by a Continuing Stockholder will not change as a result of the Reverse Stock Split. The 18-month Note bears a low interest rate of 0.25% per annum, carries no commitment fee or original issue discount and is subject to an initial minimum return hurdle of 1.11x within the first four months of the Note's term that scales up to 1.35x over its term. In connection with this financing, Macquarie will receive warrants for 1,035,197 shares of Applied Digital Common Stock with a strike price of $9.66 per share.

08:33 EST Verses Technologies provides end of year update - VERSES AI announces milestones for the year end update of significant progress in research and product development. VERSES is seeing very positive results during its internal testing of the Atari challenge and anticipates providing an update on its progress on the Atari 10k Challenge in December. The Atari 100K Challenge, introduced in 2015, involves producing a single AI model that can be trained to meet or beat human-level performance on a pool of up to 26 classic Atari games. The AI model must learn directly from pixel data, using only the score as a reward signal. Leadership will provide broader context around benchmarking and showcase early results in comparison to other AI models. Genius has matured into a suite of tools for machine learning practitioners to model complex dynamic systems and generate autonomous intelligent agents that continuously reason, plan, and learn. The Company expects to release a software update to beta users in December, which, based on user feedback, includes several improvements to the runtime environment, model building tools, performing inference, and lifecycle management to enable users to design and deploy Genius Agents. VERSES anticipate offering Genius commercially to select partners in the coming months. In December, VERSES researchers will attend the 38th Annual Conference on Neural Information Processing Systems held in Vancouver, Canada from December 10-15. The event includes over 16,000 registrations and 3,500 accepted papers in 2023. Only 26% of submitted papers are accepted and this year 10 papers from VERSES were accepted with topics spanning, among other areas, active inference, predictive coding, embodied agents, and robotics. Professor Karl Friston will present at the NeuroAI workshop entitled, "The three faces of AI," and participate in a panel discussion on the fusion of AI and Neuroscience with fellow pioneer Yoshua Bengio. The company anticipates additional commercial activity from existing Genius partners, current commercial partners such as Analog, and new commercial relationships through the end of 2024 and continuing throughout 2025.

08:33 EST Future FinTech announces update of its blockchain division - Future Fintech Group announced an update of the Company's Blockchain Business Division. The new focus of the Blockchain Business Division will be to develop and grow new blockchain businesses such as high-performance computing, web3 technology, artificial intelligence, and other blockchain related projects. The Blockchain Business Division will continue to manage its existing businesses to include coordinating its operations, developing business synergies and executing on its strategic growth plan.

08:31 EST Applied Digital closes $150M senior secured note - Applied Digital announced that the Company, through its subsidiary, APLD Holdings 2, LLC, closed a $150 million senior secured debt financing with Macquarie Equipment Capital, Inc., a division of Macquarie Group's Commodities and Global Markets' business. APLD Holdings 2, LLC issued a Promissory Note for the full $150 million in gross proceeds on November 27th, 2024, and simultaneously repaid its obligations under the Senior Secured Credit Facility with CIM Group, removing encumbrances on assets outside of APLD Holdings 2, as well as the parent guarantee. The remaining net proceeds will be used to repay other outstanding debt and pay transaction expenses. The 18-month Note bears a low interest rate of 0.25% per annum, carries no commitment fee or original issue discount and is subject to an initial minimum return hurdle of 1.11x within the first four months of the Note's term that scales up to 1.35x over its term. In connection with this financing, Macquarie will receive warrants for 1,035,197 shares of Applied Digital Common Stock with a strike price of $9.66 per share.

08:30 EST P10 appoints Mike Goodwin as CIO - P10 announced the appointment of Mike Goodwin as Chief Information Officer, effective December 2, 2024. Mr. Goodwin will lead the Company's data, technology, and infrastructure function, providing strategic leadership across the P10 platform. In this role, Mr. Goodwin will oversee key initiatives, including data aggregation, performance metrics, and the strategic application of artificial intelligence to firm-wide data. Most recently, he served as Chief Technology Officer and Chief Information Security Officer for a private equity real estate investment manager.

08:29 EST Information Services provides reminder on ticker symbol change on TSX - Information Services Corporation would like to remind the market that the Company's stock ticker symbol on the Toronto Stock Exchange will change from "ISV" to "ISC" effective as of market open, today, Monday, December 2, 2024. As a result of this change, "ISC" will now be the ticker symbol for Information Services Corporation's common shares listed on the TSX. The change allows for improved and synchronized brand alignment for the stock and the Company. No action is required by ISC's shareholders in connection with the ticker symbol change. The CUSIP number for ISC's Class A Limited Voting Shares remains unchanged, and no steps need to be taken with respect to previously issued share certificates, as these are not affected by the symbol change.

08:27 EST Sernova provides update on strategic initiatives - Sernova announced key initiatives that underscore the company's strategic progress. On November 12, at the Riyadh Global Medical Biotechnology Summit, Sernova entered into a non-binding letter of intent with HealthGena and GOLDTRACK Ventures regarding 'Project REEM Ventures' to explore opportunities for product development and commercialization initiatives in the Kingdom of Saudi Arabia to address the growing incidence of type 1 diabetes. 'Project REEM Ventures' is a collaboration initiative between Sernova, HealthGena and GOLDTRACK Ventures. HealthGena is a Riyadh-based business accelerator with a focus on biotechnology innovation. GOLDTRACK Ventures is a German-regulated venture capital manager based in Leipzig, Germany, specializing in Life Science investments. A definitive agreement has not been entered into. Additionally, Sernova is honored to welcome Dr. Robert Gabbay who will serve in a clinical advisory role. Dr. Gabbay brings a significant wealth of expertise in diabetes care and research, having most recently served as Chief Scientific and Medical Officer at the American Diabetes Association, and previously as Chief Medical Officer at the Joslin Diabetes Center, one of the world's leading diabetes research organizations. His expertise will be instrumental as Sernova advances in clinical trial development and product innovation.

08:26 EST Golden Matrix's Meridianbet enters final phase of Brazil licensing - Golden Matrix Group announced that its subsidiary Meridianbet has received formal notice from Brazil's Ministry of Finance, through its Secretariat of Prizes and Betting division, that it may proceed with the licensing process to operate in the country. This critical milestone affirms Meridianbet's compliance with Brazil's regulatory requirements and marks a significant step toward entering one of the world's most promising gaming markets. The notice enables the company to move forward with paying the licensing fee and submitting additional documentation, including proof of certification. Meridianbet has already allocated the necessary funds to finalize the licensing payment and will now move forward with fulfilling all conditions to ensure its place on the list of licensed operators authorized to serve Brazilian customers beginning January 1, 2025.

08:24 EST Veon's Kyivstar launches GenAI Lab with AWS - VEON announces the launch of a generative AI lab by Kyivstar in partnership with Amazon Web Services. This initiative will help Ukrainian enterprises introduce AI technologies with the aim to enhance business processes and contribute to the country's long-term economic recovery. Harnessing the power of AWS cloud solutions, the new lab will deliver AI services, such as text and visual content generation, augmented intelligence-based chatbots, virtual assistants, and more. These tools will help to enhance operational efficiencies for Ukrainian businesses, create competitive advantages and support long-term growth. In addition to serving Ukrainian enterprises, Kyivstar and Kyivstar Tech will also offer services like cloud migration and analytics to international markets, building up Ukraine's technology export capacity.

08:23 EST Oryzon Genomics issued 'decision to grant' notice for Russian patent - Oryzon Genomics announced that the Russian Patent Office has issued a "Decision to grant" communication for Oryzon's Russian patent application RU2021130172, titled "Methods of treating borderline personality disorder". This patent relates to vafidemstat, Oryzon's LSD1 inhibitor in clinical development for the treatment of psychiatric disorders, including borderline personality disorder and schizophrenia. The "Decision to grant" is a formal communication from the Russian Patent Office indicating that the patent application has reached the stage where it is allowed for issuance as a patent. Once granted, this Russian patent will not expire until at least 2040, excluding any potential patent term extension, which could provide additional years of protection. Oryzon has also received "Decision to grant" communications for corresponding patent applications in Europe and Mexico, and a patent has already been granted in Japan. Patent applications are also pending in other relevant markets. Additionally, Oryzon recently secured granted patents in Europe, Australia, Korea, Malaysia, and Russia under another patent family that covers the use of vafidemstat for the treatment of aggression and social withdrawal. Patent applications in additional countries are pending. These patents will not expire until at least 2038, excluding any potential patent term extensions.

08:22 EST J-Long Group announces delay in record date for share consolidation - J-Long Group is delaying the record date and effective time for the proposed share consolidation of its Ordinary Shares at a ratio of 1-for-10, until it receives approval to proceed from the Nasdaq Stock Market. The Company's Ordinary Shares, both before and after the Reverse Stock Split, will continue to trade under the existing ticker symbol "JL." The Company's members previously approved the reverse stock split and granted the Company's board of directors the authority to determine the final reverse stock split ratio and when to proceed with the reverse stock split at a Special Meeting of Stockholders held on November 18, 2024. The Company will file an Amendment to its Memorandum and Articles of Association to effect the share consolidation/reverse stock split at the ratio of 1-for-10 when the record date and effective time have been set following Nasdaq approval. The primary goal of the Reverse Stock Split is to increase the per share market price of the Company's Ordinary Shares to meet the minimum per share bid price requirement for continued listing on the Nasdaq Stock Market. The CUSIP number for the Company's Ordinary Shares will change following the reverse stock split.

08:20 EST Evaxion to present preclinical proof-of-concept for ERV cancer vaccine concept - Evaxion Biotech will present preclinical Proof-of-Concept for its precision cancer vaccine concept, targeting non-conventional ERV tumor antigens shared across patients at the ESMO Immuno-Oncology Congress, taking place from December 11-13, 2024, in Geneva, Switzerland. The data to be presented stems from studies in human cells and mouse tumor models. The studies investigated human T-cell responses and mouse tumor growth inhibition induced by precision ERV vaccine targets identified using Evaxion's AI-Immunology platform. AI-Immunology can select ERV antigens for precision therapeutic cancer vaccines, offering therapeutic options for multiple specific cancer types and potentially enabling treatment for patients who are unresponsive to conventional cancer immunotherapy. The new concept of deploying ERVs as vaccine targets allows for designing precision cancer vaccines that could be effective across diverse immune system characteristics, making them suitable for a wide range of patients. Evaxion plans to utilize this now preclinically validated concept to design new precision vaccine candidates to complement our existing pipeline of personalized cancer vaccines.

08:19 EST Amentum appoints Darren Burton as chief people officer - Amentum announced the appointment of Darren Burton as chief people officer, effective immediately. Burton will lead all aspects of the company's talent strategy and talent management that supports a diverse global workforce. Most recently, Burton served as the chief people officer at Eightfold AI, an AI-based talent intelligence platform provider.

08:18 EST Elutia awarded cardian rhythm management devices agreement with Premier - Elutia (ELUT) announced it has been awarded a national group purchasing agreement for Cardiac Rhythm Management Devices with Premier (PINC). Effective November 15, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the EluPro Antibiotic-Eluting BioEnvelope, the company said in a statement. "We are thrilled to bring EluPro to a broader audience through this new agreement with Premier," said Dr. Randy Mills, Elutia's CEO.

08:15 EST LifeVantage returns TrueScience Hydrating Lip Oil to U.S. Market - LifeVantage Corporation is elevating lip care this holiday season by bringing back the exclusive TrueScience TruePout Hydrating Lip Oil to the US market. Available starting today and sold as a pack of three, this luxurious lip oil provides a practical yet indulgent solution for keeping lips smooth, glossy, and nourished throughout dry winter months. Infused with the subtle sweetness of French Vanilla and formulated with clean, plant-based ingredients, the lip oil is a perfect, giftable add-on to any order of activating products and is an essential addition to seasonal self-care routines.

08:14 EST Merus, Partner Therapeutics enter agreement for Zenocutuzumab commercialization - The company states: "Merus N.V. and Partner Therapeutics, Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab for the treatment of NRG1 fusion-positive cancer in the United States (U.S.). Under the terms of the agreement, following a specified transition period, PTx will assume full rights to U.S. commercialization of Zeno for the treatment of NRG1+ cancer. In exchange for the rights granted under the license agreement, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales of Zeno in NRG1+ cancer in the U.S. for any potential future sales. A Biologics License Application for Zeno is currently under review by the U.S. Food and Drug Administration for the treatment of patients with previously treated NRG1+ non-small cell lung cancer and pancreatic cancer."

08:12 EST Hepion Pharmaceuticals' shareholder letter urging support for Pharma Two B deal - Hepion Pharmaceuticals has sent an open letter to shareholders urging them to vote for Hepion's proposed merger with Pharma Two B Ltd. at the Company's upcoming Special Meeting of Stockholders on December 12, 2024, stating: "Dear Shareholders of Hepion Pharmaceuticals, We are writing to encourage your support for Hepion's proposed merger with Pharma Two B, which, we believe, best positions the Company's shareholders to maximize the value of their investment. Since the Company's formation over a decade ago, Hepion has worked on developing new drugs aimed at addressing critical diseases with the goal of improving the lives of a significant patient population. Regrettably, these efforts have not yielded the desired results and, after conducting a thorough review of strategic alternatives, Hepion's board of directors concluded a merger with Pharma Two B is in the best interests of all shareholders. We therefore urge you to VOTE FOR this transformational transaction. As outlined in Hepion's definitive proxy statement dated November 8, 2024 (see link: Hepion Proxy Statement 2024 Special Meeting), the continued clinical development of the Company's drug pipeline has become increasingly challenging due to numerous risk factors- including Hepion's inability to continue funding such development and the investment community's waning appetite for follow-on financing given the deteriorating risk profile. Quite simply, the Company lacked the financial resources to advance its clinical trials and the capital markets reflected no interest in funding further development of Hepion's pipeline on acceptable terms. Fortunately, the Company's review of strategic alternatives yielded a compelling opportunity to merge with Pharma Two B, a late-clinical stage biotechnology company developing an innovative treatment for Parkinson's Disease. Upon consummation of the proposed merger, Hepion's shareholders will be able to participate in the potential upside of Pharma Two B's promising product candidate known as P2B001. Furthermore, while Pharma Two B has indicated it has no plans to advance the clinical development of Hepion's legacy drug pipeline, Hepion remains committed to monetizing its value for the benefit of all shareholders. Although its efforts to date have not yielded any formal indications of interest, any such monetization could potentially provide further upside beyond Pharma Two B's compelling prospects. Of course, there can be no guaranty of the magnitude and timing of any potential sale, if at all. In the event Hepion's proposed merger with Pharma Two B does not receive the required shareholder support, the Company faces potentially dire consequences due to its limited financial resources. A stand-alone Hepion would be unable to fund the continued development of its legacy drug pipeline and would likely face delisting of its common stock from Nasdaq and potential bankruptcy. Any adjournment to solicit additional shareholder support could erode precious financial resources. Clearly, there is a better path forward for Hepion's shareholders. Pharma Two B presents an opportunity to share in the potential upside of its innovative drug candidate to treat Parkinson's Disease. P2B001's development is already more advanced than any candidates in Hepion's legacy pipeline and the post-merger company is expected to be well-funded to advance continued clinical trials with filing of a New Drug Application with the FDA on the horizon. We therefore strongly urge you to VOTE FOR Hepion's proposed merger with Pharma Two B. Please vote today to approve this important transaction. EVERY VOTE COUNTS! No matter how many shares you may own, the outcome of the special meeting may have a material impact on the value of your investment."

08:11 EST Cinemark achieves multiple records during Thanksgiving holiday period - Cinemark announced that it achieved multiple all-time domestic records across box office, premium formats, and food and beverage sales throughout the Thanksgiving holiday period. Moviegoing across all genres led Cinemark to break multiple domestic records: best Thanksgiving five-day box office; highest Thanksgiving Day box office; most single-day attendees in the post-pandemic era on Friday, November 29; highest single-day food and beverage revenue ever on Friday, November 29; among one of the biggest food and beverage weekends of all time; top-grossing November premium format weekend of all time, including D-BOX motion seats and Cinemark XD. Bolstered by the domestic box office record performance over the Thanksgiving holiday, the company achieved its second-best November box office ever.

08:10 EST Allurion Tech announces NYSE acceptance of plan to regain listing compliance - Allurion Technologie announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange stating that the NYSE has accepted the Company's previously submitted plan to regain compliance with the NYSE's continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual . The Company expects to have until March 1, 2026 to regain compliance with the NYSE's Minimum Market Capitalization Standard. "We are pleased to have reached this milestone in collaboration with the NYSE," said Dr. Shantanu Gaur, Founder and Chief Executive Officer of Allurion. "We are looking forward to executing on our plan in our ongoing efforts to increase value for our shareholders."

08:09 EST Foxo Technologies announces results of special meeting of shareholders - FOXO Technologies announces results of its Special Meeting of its Shareholders that was held on Friday, November 29, 2024. As previously announced, the Board of Directors of the Company had authorized a virtual meeting of its shareholders to be held on Friday, November 29, 2024, at 10:30 a.m. Eastern Standard Time to seek shareholder approval for several proposals. At the Special Meeting, a total of 16,773,176 of the Company's issued and outstanding shares of Class A common stock held of record as of November 15, 2024, the record date for the Special Meeting, were present either in person or by proxy, which constituted a quorum. The Company's stockholders voted on the following proposals at the Special Meeting, each of which received sufficient votes for approval. Until recent weeks, the Company was at risk of the trading price of its Class A Common Stock falling below the $0.10 minimum requirement for NYSE American continued listing requirements and the Board of Directors determined it was prudent and necessary to ask the shareholders to approve a reverse stock split of our issued and outstanding Class A Common Stock any time before September 30, 2025, at a ratio ranging from one-for-five to one-for-one hundred with the exact ratio within such range to be determined at the sole discretion of the Company's Board of Directors, without further approval or authorization of our stockholders before the filing of an amendment to the Certificate of Incorporation effecting the proposed Reverse Split. The Company has entered into an Exchange Agreement with a debt holder who it has been unable to repay, and the Company desires to have the debt holder exchange their debt to equity. The Company asked its shareholders to approve, for purposes of complying with NYSE American Rule 713, the issuance of shares of Class A Common Stock in an amount equal to or in excess of 20% of our Class A Common Stock that was outstanding immediately prior to the Exchange Agreement when it was entered into but not exceeding 11,288,568 shares. The debt outstanding was approximately $1,945,000 at September 30, 2024. The Company has entered into an agreement with ClearThink Capital Partners, LLC that will give the Company access to a $5 million Equity Line of Credit the Company can draw on if needed to support the business objectives of the Company. The Company asked its shareholders to approve, for purposes of complying with NYSE American Rule 713, the issuance of shares of Class A Common Stock in an amount equal to or in excess of 20% of our Class A Common Stock outstanding immediately prior to such issuance in connection with the Strata Purchase Agreement dated October 13, 2023 with ClearThink Capital Partners as supplemented by the Supplement to Strata Purchase Agreement, dated as of October 13, 2023, and as amended, with ClearThink Capital Partners whereby ClearThink agreed to purchase up to $5,000,000 of shares of our Class A Common Stock and in connection with the Finder's Fee Agreement, dated as of October 9, 2023, as amended with J.H. Darbie & Co., Inc., a registered broker-dealer but not exceeding 40,000,000 shares. The Company entered into an agreement with an institutional investor to receive up to $2.5 million in debt funding. The Company has received $1 million at this time and asked its shareholders to approve, for purposes of complying with NYSE American Rule 713, the issuance of shares of Class A Common Stock in an amount equal to or in excess of 20% of our Class A Common Stock outstanding immediately prior to such issuance in connection with the Securities Purchase Agreement with an institutional investor pursuant to which the Company agreed to issue to the Purchaser and subsequent purchasers who will also be parties to the SPA Senior Notes in the aggregate principal amount of up to $2,800,000 but not exceeding 30,800,000 shares.

08:09 EST Nano Labs announces $50M BTC purchase plan - Nano Labs announced its plan to purchase and hold $50M worth of Bitcoin over the next five years. This strategic decision underscores the Company's confidence in BTC as a long-term store of value and a foundational asset within the rapidly evolving Web 3.0 ecosystem.

08:08 EST Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA - Rigel Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome, LR-MDS. R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies.

08:06 EST Natera publishes cfDNA data in Obstetrics & Gynecology - Natera announced that Obstetrics & Gynecology published the company's clinical validation study on its cell-free DNA, or cfDNA, Fetal RhD noninvasive prenatal test. Natera's study is the largest clinical validation of a fetal RhD test performed in the United States to date, with fetal RhD status confirmed via newborn serology in 655 RhD-negative pregnant patients. The study provides compelling scientific evidence on the ability of Natera's Fetal RhD NIPT to identify fetal RhD status, and demonstrates its potential to assist patients and clinicians in the prevention and management of RhD alloimmunization. In addition, Natera's next generation sequencing, or NGS-based Fetal RhD test can identify RHD pseudogene and other hybrid variants that are more commonly occurring in people of non-European ancestries. Key highlights of the study include: 356/356 fetuses were correctly identified as fetal RhD positive. Of the 297 RhD-negative fetuses, 295 were correctly identified as RhD-negative. Positive predictive value for the test was 99.4% and negative predictive value was greater than 99.9%. The study included a representative mix of race and ethnicities in the RhD-negative U.S. population.

08:05 EST Critical Metals receives notice that EIA not required for Wolfsberg project - Critical Metals announced that after an intensive examination, the Company has received a notice from the Carinthian state government that an Environmental Impact Assessment is not required for the Wolfsberg Lithium Project, which is strategically located in Austria. This is an important step on the way to realizing the project and establishing a European battery supply chain for electromobility. Now, as it relates to underground mining where the surface area required by the above-ground facilities is less than 10 hectares, as is envisaged for lithium mining on the Koralpe, no EIA is required by law. The assessment by the EIA authority covered the entire project on the Koralpe, i.e. the planned underground mining, the surface mining facility for the production of a spodumene concentrate, the energy supply lines and necessary clearance, and the refilling of the empty mining chambers with the surplus mining material, as well as an examination of interactions with other projects. The audit was carried out by official experts from the departments of forestry, nature conservation, geology, hydrogeology, waste management, chemistry, process engineering, water ecology and water management as well as torrent and avalanche control. On the basis of this comprehensive case-by-case examination, in which all relevant facts of the EIA Act were taken into account, the EIA authority came to the conclusion that an EIA was not necessary.

08:04 EST J&J seeks U.S. FDA approval for pediatric indications for TREMFYA - Johnson & Johnson announced the submission of two supplemental Biologics License Applications, sBLAs, to the U.S. Food and Drug Administration, FDA, seeking approval of TREMFYA for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis, PsO, and children 5 years of age and older with active juvenile psoriatic arthritis. The PsO submission is based on data from the Phase 3 PROTOSTAR study in pediatric patients with moderate to severe plaque PsO and bridging pharmacokinetic data from the Phase 3 VOYAGE 1 and 2 studies in adult patients with moderate to severe plaque PsO. The jPsA submission is based on PK extrapolation analyses from adult PsA studies and TREMFYA efficacy and safety data from the PROTOSTAR study.

08:03 EST Esperion announces new drug submissions in Canada for NEXLETOL - Esperion has filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol and cardiovascular risk. "These submissions mark another pivotal milestone towards bringing our potentially lifesaving medications to the millions of patients around the world who need it," said Sheldon Koenig, President and CEO of Experion. "Heart disease remains the number one cause of death globally, so we look forward to the opportunity to provide NEXLETOL and NEXLIZET as LDL cholesterol lowering and cardiovascular risk reduction treatment options for healthcare providers and patients in Canada."

07:59 EST Haleon appoints Sta-Romana as Chief Customer Officer for its U.S. business - Haleon announces the appointment of Joe Sta-Romana as Chief Customer Officer, CCO for its US business, effective December 1, 2024. In this role, Joe will lead the organization's customer strategy, driving growth and transformation in the US market.

07:54 EST Jeffs' Brands saw $1.2M in Fort Products sales from Amazon during Black Friday - The company states: "Jeffs' Brands announced that its wholly owned subsidiary, Fort Products Ltd., marked exceptional performance during November 2024, reaching over $1.2 million in sales from its platform on the Amazon Marketplace in the UK and Europe, according to its seller dashboard. This represents an impressive 83% growth compared to approximately $659,000 in November 2023. Fueled by the high demand of the Black Friday shopping season and consistent customer preference for its products, November 2024 stands as the best sales month in Fort's history since 2015."

07:52 EST Avicanna completes first delivery of topical products to pharmaceutical company - Avicanna announced the initial delivery of its proprietary topical products into Europe as a part of the previously announced exclusive supply agreement with a multinational pharmaceutical company. The products include 3% CBD localized cream and the 2% CBD and 0.5% CBG transdermal gel utilizing the Company's patented deep tissue technology. The 3% CBD localized cream, as well as the 2% CBD and 0.5% CBG transdermal gel products completed human irritation and real-world evidence studies. Avicanna previously disclosed the exclusive supply agreement for the products to multinational pharmaceutical company, which required pre-requisite testing and analysis for registration under cosmetics regulations prior to importation into the German market for their initial launch. The multinational pharmaceutical company manufactures and markets a wide range of pharmaceutical products and other products across 4 continents and has established commercial infrastructure in the European region that will be utilized for the initial launch of the selected products. The multinational pharmaceutical company has committed to launch the initial products in 6 European countries during 2025 with expectations of further expanding throughout the European region shortly after. Avicanna has earned licensing fees for meeting specific milestones this year. Additionally, the parties agreed to specific minimum order quantities and commercial milestones for the multinational pharmaceutical company to maintain the exclusivity.

07:51 EST Revolution Medicines provides updates from RAS(ON) inhibitor combo studies - RAS(ON) Inhibitor Combination Studies: RMC-6236 with Pembrolizumab: RMC-LUNG-101B is an arm of the Phase 1b study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS mutant NSCLC. A total of 20 patients treated with RMC-6236 at 200 mg QD and pembrolizumab at the standard dose of 200 mg once every three weeks were evaluated as of an October 28, 2024 data cutoff date. The median duration of treatment for these patients was 2.3 months. The combination of RMC-6236 with pembrolizumab was generally well tolerated and the safety profile was consistent with previously reported results for the individual agents. TRAEs of Grade 1 aspartate aminotransferase elevation were reported in two patients and a TRAE of Grade 2 AST elevation was reported in one patient. A TRAE of Grade 1 alanine transaminase elevation was reported in one patient and a TRAE of Grade 3 ALT elevation was reported in one patient. The mean dose intensity for RMC-6236 was 97%. Next steps: The company believes the data from this study support continued evaluation of the combination of RMC-6236 with pembrolizumab in 1L NSCLC patients. RMC-6291 and RMC-6236 RAS(ON) Inhibitor Doublet: RMC-6291-101 is a Phase 1b study of RMC-6291 in combination RMC-6236 in patients with RAS G12C mutant solid tumors. The study has evaluated RMC-6291 at doses of 100 mg or 200 mg BID and RMC-6236 at a dose range of 100 mg to 300 mg QD. As of an October 28, 2024 data cutoff date, 74 patients were evaluated for safety with a median duration of treatment of 2.3 months. The combination of RMC-6291 with RMC-6236 was generally well tolerated across all dose levels evaluated. The most common TRAEs were rash and GI-related toxicities that were primarily Grade 1 or 2 in severity. No Grade 3 or higher TRAEs were observed in greater than 5% of patients. One Grade 4 TRAE of hypokalemia was associated with Grade 3 diarrhea. TRAEs leading to dose interruption or reduction occurred in 30% and 10% of patients, respectively. The mean dose intensities for RMC-6291 and RMC-6236 were 95% and 92%, respectively. A subset of efficacy-evaluable patients with colorectal cancer who were previously treated with a KRAS(OFF) G12C inhibitor was evaluated for antitumor activity on treatment with RMC-6291 with RMC-6236. As reference values, the company also reported that the ORR for patients with CRC treated with RMC-6236 monotherapy at a dose of 300 mg daily in the RMC-6236-001 study as of a data cutoff date of September 30, 2024 was 9%, and the ORR for patients with CRC previously treated with a KRAS(OFF) G12C inhibitor who were subsequently treated with RMC-6291 monotherapy at a dose of 200 mg twice daily in the RMC-6291-001 study as of a data cutoff date of October 28, 2024 was 0%. In the combination study, patients with CRC who were previously treated with a KRAS(OFF) G12C inhibitor and who received their first doses of the two study drugs at least 8 weeks prior to data cutoff were included in the analyses. The ORR was 25%, including one patient with an unconfirmed complete response, and the DCR was 92%. The median treatment duration was 2.3 months. Next steps: The company believes the data from this combination study support continued development of RAS(ON) doublets in a broad range of tumor types and earlier lines of therapy. RMC-6291 with Pembrolizumab: RMC-LUNG-101A is an arm of the Phase 1b study of RMC-6291, a RAS(ON) G12C-selective inhibitor, in combination with pembrolizumab, with or without chemotherapy, in patients with RAS G12C mutant NSCLC. A total of 15 patients treated with RMC-6291 at 200 mg twice daily and pembrolizumab at the standard dose of 200 mg Q3W were evaluated as of an October 28, 2024 data cutoff date. As of this date, 47% of these patients had been on treatment for 60 days or more. The combination of RMC-6291 with pembrolizumab was generally well tolerated and the safety profile was consistent with previously reported results for the individual agents. A TRAE of Grade 1 AST elevation was reported in one patient and a TRAE of Grade 1 ALT elevation was reported in one patient. There were no TRAEs of Grade 2 or higher AST or ALT elevations reported. The mean dose intensity for RMC-6291 was 98%. Next steps: The company believes the three pairwise combinations of RMC-6291 with RMC-6236, RMC-6236 with pembrolizumab and RMC-6291 with pembrolizumab justify investigation of the triplet combination of RMC-6291 and RMC-6236 with pembrolizumab as a potential chemotherapy-sparing option for patients with 1L NSCLC.

07:44 EST Kellner Group urges AIM ImmunoTech stockholders to vote for its nominees - Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney issued a press release in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech. The release said in part, "It is clear that the entrenched AIM Board will say anything and do anything, no matter the terrible consequences to stockholders, in their self-interested effort to keep their board seats at all costs. These are the relevant facts: Each of the Kellner Group Nominees will bring desperately needed skills, resources, experience and credibility to AIM's Board - each of them is an accomplished and respected business person in their field and none of them has any criminal history whatsoever. There are no other AIM stockholders or other third parties involved in the Kellner Group's activities, nor were there any other AIM stockholders or other third parties involved in Mr. Kellner's nominations and solicitation for AIM's 2023 annual meeting of stockholders. The AIM Board's tired and pathetic attempt to connect the Kellner Group to Mr. Tudor and Mr. Xirinachs - who have no role whatsoever with the Kellner Group - is just another misleading distraction from their own fiduciary duty breaches, the plummeting stock price that continues to reach new lows and the desperate financial condition of AIM under their watch."

07:40 EST Ocular Therapeutix announces over 300 subjects randomized in SOL-1 - Ocular Therapeutix announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI, and the trial is expected to close randomization this week. This is the first registrational clinical trial of AXPAXLI in wet age-related macular degeneration, which remains on track to report topline data in the fourth quarter of 2025.

07:38 EST Rumble to host 4th Season of 'Surviving Barstool' - Rumble announced that the much-anticipated fourth season of "Surviving Barstool" will move to Rumble, unedited and uncensored, beginning Monday, December 2, 2024. Rumble users and Barstool fans can subscribe to the Barstool Sports Rumble channel here and tune in to watch this season here. YouTube will only carry the censored version of Surviving Barstool. "Surviving Barstool" follows twenty-four of the biggest Barstool employees competing against each other for a $250,000 prize while trapped in the office. The final winner will be decided by the employees who were voted out along the way.

07:38 EST Xoma Royalty acquires Pulmokine for $20M - XOMA Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension through its acquisition of Pulmokine Inc., a privately held company. In 2017, Pulmokine licensed seralutinib to Gossamer Bio, Inc., and in 2024, Gossamer Bio signed a global collaboration and license agreement with Chiesi Farmaceutici S.p.A. XOMA Royalty acquired all outstanding shares of Pulmokine for a $20 million cash payment at closing. In addition, XOMA Royalty will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders. XOMA Royalty's net royalties will range from the low to mid-single digits on commercial sales; additionally, the Company will retain up to $25 million of the milestone payments.

07:35 EST Nut Tree, Caspian Capital oppose merge of Martin Midstream, Martin Resources - Nut Tree Capital Managemen and Caspian Capital, which together with their affiliates have combined exposure in Martin Midstream Partners of approximately 13.6% of the outstanding common units, have filed definitive proxy materials with the Securities and Exchange Commission, SEC, opposing the sale of MMLP to Martin Midstream Resource Corporation for $4.02 per common unit to be voted on during the Company's upcoming meeting. In connection with the filing of the definitive proxy materials, Nut Tree and Caspian have mailed a letter to MMLP's common unitholders urging them to vote "AGAINST" the Merger at the Special Meeting. As discussed in the definitive proxy materials and the letter, Nut Tree and Caspian oppose the Merger and believe that: MMLP's common units are worth far more than the $4.02 per unit price offered in the Merger; The Company relied on a deeply flawed financial analysis used to justify the Merger that ignored the future prospects for MMLP, which stand to create additional value for unitholders; and The massive conflicts of interest in the Merger and its negotiation process demand the highest degree of scrutiny and skepticism from MMLP unitholders.

07:34 EST Abeona Therapeutics announces new employee inducement grants - Abeona Therapeutics has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On November 30, 2024, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to nine individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 44,700 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee's continued employment with Abeona on the applicable vesting dates.

07:34 EST Cytokinetics announces FDA acceptance of NDA for aficamten - Cytokinetics announced that the U.S. Food & Drug Administration has accepted the company's New Drug Application for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy. The FDA assigned the NDA a standard review with a Prescription Drug User Fee Act target action date of September 26, 2025. The FDA is not currently planning to hold an advisory committee meeting to discuss the application.

07:26 EST Aya Gold & Silver announces first silver pour at expanded Zgounder Mine - Aya Gold & Silver announced the first silver pour from its expanded Zgounder Mine in the Kingdom of Morocco. The first silver pour was completed on November 27, 2024. Highlights: The first full silver pour was completed on November 27, 2024: First silver pour achieved from the new mill throughout the entire circuit. Hot commissioning is now complete with the gravity circuit currently being commissioned. Recoveries of over 80% recorded and improving: Improvement as the circuit stabilises and mill head grade increases. The mill is currently being fed with marginal ore to minimize silver lost through ramp up. All equipment / circuits are operating as expected. Operations ramping up: Nameplate odf 2,000 tonnes per day was achieved on November 29, 2024, less than a month after first ore in mill. Availability, recovery and throughput continue to improve daily, reinforcing our confidence in reaching commercial production before end of year. "This milestone brings us closer to the start of commercial production at our expanded Zgounder mill in the coming weeks and marks our transition into a tier-one, pure-play, and profitable silver producer," said Benoit La Salle, President & CEO. "I am incredibly proud of our team's hard work and extend my sincere thanks to everyone who contributed to the successful, on-budget completion of this expansion. With a full ramp-up planned for next year, we are encouraged by the strong operating indicators, overall performance, and continued optimization of our deposit."

07:23 EST Vitalhub announces increase to credit facilities - Vitalhub has amended and expanded its existing credit facilities with The Bank of Nova Scotia to further strengthen the Company's financial flexibility. Under the terms of the amendment, the Company's total committed borrowing capacity has increased to $65 million from $33 million. The amended credit facilities consist of a $60 million term facility and a $5 million revolving facility. Subject to approval at the time of request, the Company has the ability to increase the amount that can be drawn pursuant to an accordion facility for up to an additional $10 million. The credit facilities remain undrawn as of today's date.

07:21 EST Belo Sun Mining announces federal court ruling on INCRA agreement - Belo Sun Mining reports that the Federal Court of Altamira, has ruled on a case filed by the Federal Public Defender's Office and the Public Defender's Office of the State of Para in 2022 contesting the agreement made between the Company and the Brazilian National Institute of Colonization and Agrarian Reform in November 2021. The Judge has declared the INCRA Agreement null and void on procedural grounds. The ruling stated that INCRA had not completed an ordinance required to announce the measure taken by the government on the declassification of the area from agrarian reform. However, the Judge rejected the DPU's request to annul the Volta Grande environmental licensing process and as requested by the Company excluded the DPE from the lawsuit. The Company will be evaluating all legal options, including a potential appeal of the decision and continuing to work with INCRA. Commenting on the Federal Court of Altamira ruling, Ms. Ayesha Hira, Interim President and CEO of Belo Sun, said, "We look forward to working with INCRA on the next steps following the ruling by the Federal Court in Altamira. We will also be evaluating all the legal options available to the Company. We believe PVG is well positioned to bring benefits to the surrounding communities, local farmers, landholders and the municipality. We continue to work to benefit the region and all stakeholders as we look to advance PVG."

07:19 EST Olema Oncology up 13% at $11.40 after entering supply pact with Novartis

07:18 EST McEwen Mining announes new assay results from Grey Fox deposit - McEwen Mining announced new assay results from its Grey Fox deposit, part of the Fox Complex located in the Timmins region of Ontario, Canada. Grey Fox is located in the southern part of the Black Fox property and comprises six zones, known as Gibson, Whiskey Jack, Contact, 147, 147NE and Grey Fox South. High-grade drill hole results include: 10.2 grams per tonne; Au over 11.1 m at Whiskey Jack. Geological investigations demonstrate similarities between the Grey Fox Deposit and the Hishikari Gold Mine. Potential for stacked epithermal gold-bearing veins over & adjacent to an orogenic gold system.

07:17 EST AirBoss of America announces credit facilities, update on strategic transaction - AirBoss of America has entered into new senior secured credit facilities consisting of aggregate financing of up to $180 million, which are replacing its current senior secured revolving credit facilities, and an update on its previously announced strategic transition. The new credit facilities consist of a revolving asset-based credit facility co-arranged by The Toronto-Dominion Bank and Canadian Imperial Bank of Commerce and a non-revolving term loan facility provided by Great Rock Capital Partners The commitments under the ABL Facility, when fully syndicated, are expected to be US$125 million and the Term Facility is for US$55 million. The maturity date under both facilities is November 29, 2027. Additional key terms of the new credit facilities include the following: Reducing the maximum applicable margin on revolving debt from 450 basis points to 225 basis points; Dividend increases above current levels are subject to certain financial conditions; Meeting certain minimum adjusted EBITDA and liquidity requirements; and Covenants related to annual capital expenditures. The Company continues to work diligently on its strategic review, evaluating a range of potential opportunities to enhance shareholder value. While no specific transactions are imminent or expected to occur in the near-term, AirBoss continues to explore potential strategic divestitures as well as the potential monetization of its real estate assets. There can be no assurance that this ongoing evaluation of strategic opportunities will result in the successful completion of any transaction, nor any assurance as to the timing or nature of any outcomes.

07:14 EST Purple Biotech reports final results from randomized Phase 2 study of CM24 - Purple Biotech reported final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma. The Phase 2 study evaluated CM24, a novel first-in-class multi-functional anti-CEACAM1 antibody, in combination with Bristol Myers Squibb's immune checkpoint inhibitor nivolumab plus stand-of-care chemotherapy in second-line metastatic PDAC patients versus SoC chemotherapy alone. CM24 is a humanized monoclonal antibody that blocks CEACAM1, a multi-faceted membrane glycoprotein that is one of the main proteins present on NETs, also acting as a pro-angiogenic and anti-apoptotic agent collectively promoting tumor invasiveness, metastasis and immune evasion. The primary endpoint of the study is OS and the secondary endpoints include PFS, ORR and disease control rate. A Bayesian methodology was used to estimate the magnitude of effect of the experimental arm versus the SoC arm in each chemotherapy cohort; the study was not powered for hypothesis testing. A total of 63 patients were enrolled, across 18 centers in the U.S., Spain, and Israel in 2 parallel and independent randomized study cohorts. The experimental arms administered patients with CM24 plus nivolumab and a choice of one of two SoC chemotherapies for second-line PDAC, dependent on prior first line therapy regimen; either gemcitabine/nab-paclitaxel or liposomal irinotecan /5-fluorouracil and leucovorin, while the control arms administered either respective chemotherapy alone. CA19-9 as well as additional exploratory biomarkers were also evaluated. Of the 63 patients enrolled, 32 were in the gemcitabine/nab-paclitaxel study and 31 were in the Nal-IRI/5FU/LV study. The gemcitabine/nab-paclitaxel-based part of the study was impacted by informative censoring of the control arm that led to an imbalance between the control and experimental arms, rendering this part of the study unsuitable for analysis; this part of the study has no impact on the CM24+nivolumab+Nal-IRI/5FU/LV portion of the study. A consistent and continuous decrease of CA19-9, a clinically validated PDAC biomarker, was observed in the experimental arm reaching a median percentage reduction from baseline of approximately 80% vs. an increase of 40% in the control arm. An additional subgroup analysis of patients, which comprised 80% of the patients in the study cohort, with a range of pretreatment serum CEACAM1 between 6,000 pg/mL and 15,000 pg/mL together with patients with pretreatment serum Myeloperoxidase levels of 200 ng/mL and 600 ng/mL, resulted in statistically significant results. Additional biomarkers analysis based on the patient pretreatment biopsies, demonstrated significant OS and PFS benefit in patients with both high tumor CEACAM and low Combined Positive Score supporting the CM24/nivolumab combined treatment and its mechanistic rationale, and may open a new opportunity for patients who are not eligible for anti-PD1 therapy in various indications The CM24+nivolumab+Nal/IRI/5FU/LV regimen was well tolerated, with the most frequent treatment emergent Grade 3 or higher adverse events being diarrhea fatigue and neutropenia. Accordingly, no meaningful difference in safety and tolerability were observed between the experimental arm and SoC arm.

07:13 EST Lightspeed announces reorganization, will impact 200 individuals - Lightspeed Commerce announced a reorganization to further optimize its operations toward executing on the Company's focused profitable growth strategy. This initiative is designed to prioritize resources for strategic areas of the business, maximizing the Company's long-term growth opportunity, and redefining the organizational structure and operations of other areas of the business. The reorganization will impact approximately 200 individuals, with the resulting savings being redeployed across other areas of Lightspeed's business, in line with the Company's strategic objective of further driving profitable growth. Lightspeed expects that the majority of the restructuring charges will be incurred in the third quarter of fiscal 2025.

07:12 EST Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint - Zai Lab (ZLAB) and Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival, or mOS, versus control. PANOVA-3 evaluated the use of Tumor Treating Fields, or TTFields, therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement. The survival rate benefit for patients treated with TTFields therapy increased over time with a 13% improvement in the overall survival rate at 12 months and a 33% improvement in survival rate at 24 months. TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 and plans to submit the PANOVA-3 results for presentation at an upcoming medical congress. Zai Lab plans to file for regulatory approval in China.

07:10 EST Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202 - The company states: "Senti Bioscience reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural kille investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia. SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3- expressing hematologic malignancies, including AML, while sparing healthy bone marrow cells. Three AML patients have been treated at the lowest dose level (1.0 billion CAR+ NK cells per dose) and, as of the data cutoff date of September 19, 2024, two achieved complete remission, confirmed by bone marrow biopsy, which includes blast reduction and recovery of blood cells to normal ranges. In addition, both patients were assessed as measurable residual disease negative after treatment, which is defined as no detectable cancer cells present in a bone marrow sample by the most sensitive locally available method. As of today, both patients continue to maintain their remission (4+ months and 3+ months, respectively). In all three patients, SENTI-202 was generally well-tolerated with an adverse event profile consistent with the use of lymphodepleting chemotherapy in patients with AML. As of the data cut, three patients with R/R AML were enrolled at the 1.0 billion CAR+ NK cells/dose level, administered three times, on days 0, 7, and 14 of a 28-day cycle following lymphodepletion with fludarabine/cytarabine. The lowest dose cohort was cleared by the Safety Review Committee and dose escalation is continuing at the 1.5 billion CAR+ NK cells/dose level. Two patients achieved CR; one after two cycles and the other after one cycle, both with absent MRD by the most sensitive methods available for the patients at the respective clinical sites. With an additional two months of follow-up since the data cut, both patients are continuing to maintain MRD negative CR status (4+ months and 3+ months, respectively). One patient had no response after one cycle of treatment and was refractory to therapy. SENTI-202 was generally well-tolerated with no dose limiting toxicities ("DLTs") and an adverse event profile consistent with other investigational NK cell therapies and patients with underlying AML receiving lymphodepleting chemotherapy. SENTI-202 transgene was detected in the peripheral circulation of all 3 patients and in all cycles, with a pharmacokinetic ("PK") profile generally consistent with other investigational CAR-NK therapy levels."

07:10 EST RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court - RedHill Biopharma announced that the Company has been awarded approximately $8 million, plus costs in a summary judgment by the Supreme Court of the State of New York, New York County, in its legal proceedings against Kukbo Co. Ltd., domiciled in South Korea. The case refers to Kukbo's failure to make agreed payments to RedHill, pursuant to a Subscription Agreement, dated October 25, 2021, and a subsequent Exclusive License Agreement, dated March 14, 2022, entered into by the two companies.

07:09 EST PTC Therapeutics enters global license, collaboration agreement with Novartis - PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NVS), for its PTC518 Huntington's disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales. Novartis will assume responsibility for PTC518's development, manufacturing and commercialization, following the completion of the on-going placebo-controlled portion of PIVOT-HD, which is expected to occur in H1 2025.

07:09 EST OraSure receives federal funding for development of Marburg Virus test - OraSure Technologies received an award through the Rapid Response Partnership Vehicle for the development of a Marburg Virus Disease rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Service. The initial contract award, valued at approximately $7.5 million over multiple years in the base period with potential value up to $11 million, funds the development to achieve U.S. Food and Drug Administration 510(k) clearance of a single-use lateral flow immunoassay intended for the qualitative detection of antigens from viruses within the Marburg virus genus. We expect that the proposed test will be intended for use with specimens from individuals with epidemiological risk factors who have signs or symptoms of MVD or from recently deceased individuals with epidemiological risk factors who are suspected to have died of MVD.

07:07 EST Autolus Therapeutics announces publication of data from FELIX study - Autolus Therapeutics announces that the New England Journal of Medicine has published data from the pivotal Phase 1b/2 FELIX study of obecabtagene autoleucel in relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia. The data demonstrate high rates of durable responses with low incidence of grade greater than or equal to3 immune-related toxicity. Of the 153 r/r B-ALL patients enrolled patients in the FELIX study, 127 received at least one obe-cel infusion and were evaluable. Eligible patients underwent leukapheresis, and bridging therapy, except blinatumomab, was permitted at the investigator's discretion. Obe-cel was administered in a bone marrow burden adjusted split dose following lymphodepletion, with a BM mandated prior to lymphodepletion to guide dosing. The second obe-cel dose was given in the absence of severe/unresolved toxicity. The primary end point was overall remission. In the pivotal cohort of patients, the CR/CRi for patients who received at least one infusion of obe-cel was 76.6% Across all infused patients, of the 91/127 with greater than or equal to5% BM blasts pre-lymphodepletion, the CR/CRi was 74.7%. Median response duration for all infused patients was 21.2 months. Median event-free survival was 11.9 months and the estimated 6- and 12-month event-free survival rates were 65.4% and 49.5%, respectively. BM burden pre-lymphodepletion correlated with median event-free survival; patients with low, intermediate, and high BM burden had event-free survival rates at 12 months of 68.0%, 54.9% and 25.0%, respectively. Median overall survival was 15.6 months and estimated 6- and 12-month overall survival rates were 80.3% and 61.1%, respectively. BM burden pre-lymphodepletion correlated with overall survival; patients with low, intermediate, and high BM burden had an overall survival rate at 12 months of 71.5%, 58.7% and 55.0%, respectively. BM burden before enrollment also influenced event-free and overall survival. Of the 127 patients infused, 99 patients responded. Of the responders, 18 patients proceeded to allo-Stem Cell Transplant while in remission at a median of 101 days post-obe-cel infusion. In 6/18, this was a second allo-SCT. Of 11 patients who had persisting CAR T cells before allo-SCT, and who had samples available post, none had CAR T cells detected following allo-SCT. There was no difference in event-free and overall survival observed between patients who received allo-SCT and those who did not. Median duration of CAR T persistence by droplet digital PCR in peripheral blood was 17.8 months. Obe-cel was associated with minimal immunotoxicity. CRS and Immune effector cell-associated neurotoxicity syndrome rates were 2.4% and 7.1%, respectively. Overall, 87 patients developed CRS, and 29 developed ICANS. Severe ICANS post-obe-cel were seen as largely limited to patients with high BM burden pre-lymphodepletion. Intensive care unit admissions occurred in 20 patients for a median of 5.5 days of which 7/20 were admitted due to immunotoxicity management. Obe-cel was approved by the Food & Drug Administration under the brand name AUCATZYL on November 8, 2024. Marketing authorization applications for obe-cel are being reviewed by the regulators in both the EU and the UK, with a submission to the European Medicines Agency accepted in March 2024, and a submission accepted by the UK MHRA in August 2024.

07:07 EST Novocure announces PANOVA-3 trial met primary endpoint - Novocure announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival, or mOS, versus control. PANOVA-3 evaluated the use of Tumor Treating Fields, or TTFields, therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement. The survival rate benefit for patients treated with TTFields therapy increased over time with a 13% improvement in the overall survival rate at 12 months and a 33% improvement in survival rate at 24 months. TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 and plans to submit the PANOVA-3 results for presentation at an upcoming medical congress. Novocure continues to follow patients in its Phase 2 PANOVA-4 trial, exploring the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment with data anticipated in 2026.

07:06 EST Ecovyst announces strategic review of AM&C - Ecovyst announced that its Board of Directors has initiated a strategic review process for its Advanced Materials & Catalysts business, AM&C. This announcement is an extension of the Board's ongoing evaluation and review of the business, aimed at maximizing shareholder value. Ecovyst expects to complete the strategic review of the AM&C business unit in Mid-2025. The strategic review may not result in any transaction or other outcome. The company does not intend to make any further public comment regarding the strategic review until it has been completed or the company determines that disclosure is required or beneficial.

07:04 EST Swvl relaunches porduct in UAE, securing four customers - Swvl Holdings announces the relaunch of its product in the United Arab Emirates. This move aligns with its strategy to expand into regional and global markets. Additionally, Swvl has secured four key customers in the UAE, marking a strong relaunch of its journey in adding value to the mobility ecosystem within the country.

07:00 EST TreeHouse to acquire Harris Tea for $205M - TreeHouse announced that it has signed a definitive agreement to acquire certain subsidiaries that operate the private brand tea business of Harris Freeman & Co. for approximately $205M, subject to customary purchase price adjustments. The acquisition includes Harris Tea's manufacturing facilities in Moorestown, New Jersey and Marietta, Georgia, and TreeHouse Foods will welcome approximately 300 Harris Tea team members. The acquisition of Harris Tea will be accretive to the company's overall growth and margins. The company has agreed to a purchase price that equals roughly 8.5x trailing-twelve-month adjusted EBITDA, or 6.5x net of synergies and the net present value of future tax benefits. This transaction is expected to close in the first quarter of 2025 and will be funded primarily with cash on hand, and fully satisfies the company's obligation under its bond indenture to either reinvest certain proceeds from the previously completed Meal Preparation sale or retire debt. Upon closing, the company expects its leverage ratio1 to be within its target range of 3.0x to 3.5x. Finally, TreeHouse Foods is reiterating its 2024 full year guidance, including the expectation of sequential improvement in volume growth and profit margin in the fourth quarter.

06:49 EST Apollo Silver provides corporate update - Apollo Silver provided a corporate update and outlook for the Company. Highlights: Successfully mitigated single asset risk and bolstered existing mineral inventory through optioning the high-grade Cinco de Mayo Silver Project in Chihuahua, Mexico. Completed C$13.5M financing. Strengthened board and management with the additions of Messrs. Alex Tsakumis and Amandip Singh, respectively. Engaged a team of highly qualified professionals with ties to the local community and a track record of success in navigating community relations and social licencing requirements, at Cinco de Mayo. Commencing maiden barite resource estimate and follow up gold exploration program at the Calico Silver Project in San Bernardino, California, in 2025. Interim President and CEO, Andrew Bowering, commented, "In what has been a productive 2024, the Company has been executing on its vision for the future. We have successfully entered into an option agreement to acquire the Cinco de Mayo Project, mitigating single asset risk. Furthermore, we completed a financing that significantly strengthens our treasury, allowing us to continue to build long term shareholder value across our portfolio of North American silver projects." On September 20, 2024, the Company entered into an earn-in and option agreement with MAG Silver and its subsidiary, Minera Pozo Seco, S.A. de C.V., pursuant to which the Company has the option to acquire Cinco de Mayo. To satisfy the Option, and acquire a 100% interest in Cinco de Mayo, the Company must first obtain the necessary licencing and permits to access the property and conduct mining activities on Cinco de Mayo, followed by completing no less than 20,000 metres of exploration drilling within five years. Upon completion of those terms and subject to the final approval of the TSX Venture Exchange, Apollo Silver must issue to MAG common shares equivalent to 19.9% of the then issued and outstanding common shares of the Company on a non-diluted basis. In addition, Apollo Silver will grant MAG the right to maintain its 19.9% stake by participating in any subsequent financing for an additional four year period. During the Option term, the Company will control all exploration and development activities on the Project and will be responsible for all expenses associated with maintaining Cinco de Mayo in good standing. On November 11, 2024, the Company announced that it closed its fully subscribed and upsized private placement of C$13.5 million. The Financing received strong support, including investment from Mr. Eric Sprott, and several institutional investors including but not limited to: Jupiter Asset Management Limited, Commodity Capital AG, Primevestfund and Terra Capital Natural Resources Fund. The Company currently has working capital of approximately C$13.5 million and is expecting to commence barite resource estimation work at Calico and additional exploration on the recent gold discovery Calico in the new year. The Company is sufficiently funded to continue its ongoing community initiatives and negotiations with the local community to restore access to Cinco de Mayo, satisfy its ongoing general working capital requirements, and be able to commence future exploration work at Cinco de Mayo, once access is restored.

06:44 EST Montage Gold to obtain 19.9% ownership stake in Sanu Gold - Montage Gold has entered into a strategic partnership with Sanu Gold Corporation, given its highly attractive exploration properties in Guinea, obtaining a 19.9% interest in Sanu through the issuance of 2.3 million basic shares of Montage equating to C$5.5 million, joining existing strategic investor AngloGold Ashanti who acquired a 14.0% stake in Sanu in September 2024. Montage will be investing alongside the Lundin Family and their associates who will obtain a 10.0% interest in Sanu by participating in the non-brokered private placement with an investment of C$2.7 million. Through the Offering, Sanu will obtain aggregate gross proceeds of approximately C$10.0 million based on a share issuance price of C$0.072. Montage management and certain insiders also intend to participate in the Offering. Sanu owns three highly attractive gold exploration permits in Guinea, located within the Siguiri Basin in proximity to AngloGold Ashanti's Siguiri gold mine, Nordgold's Lefa gold mine, Predictive Discovery's Bankan gold project, and exploration tenements held by Endeavour Mining. Sanu is currently undertaking a 10,000-meter drill programme at its Diguifara and Daina properties, comprising of up to 120 holes, where historical exploration efforts resulted in the identification of a number of mineralised gold-bearing structures. Sanu expects to use the net proceeds of the Offering to advance exploration, including geophysics and drilling on the company's Daina, Diguifara and Bantabaye gold exploration permits, and for general and administrative purposes. Montage has entered into a binding term sheet in respect of a transaction whereby Montage and Sanu will enter into an Investment Agreement and Investor Rights Agreement, which will persist so long as Montage holds at least 10% of the issued and outstanding Sanu Common Shares with the following key terms: Equity Swap: Montage will obtain a 19.9% ownership in Sanu, through a Share Exchange Transaction which results in the issuance of 76,307,155 Sanu Common Shares to Montage, and the issuance of 2,337,921 common shares of Montage to Sanu equating to a 0.67% ownership in Montage, for a total implied transaction consideration of C$5,494,115. The Share Exchange Transaction is based on a Montage share price of C$2.35 and a Sanu share price of C$0.072. Montage Shares will be issued to Sanu under an exemption from the prospectus requirements of applicable Canadian securities laws and will be subject to a hold period of four months and one day from the date of issuance to Sanu. Any Sanu sale of Montage shares will be subject to certain notice rights to enable Montage Gold to designate suitable purchaser, subject to the Investor Rights Agreement Threshold. Participation Rights: Right to participate in future equity issuances and top-up rights to maintain Montage's ownership percentage in Sanu, payable in Montage shares, cash, or a combination of either. Board Nominee: Appointment of a Montage nominee as Chairman to the Board of Directors of Sanu. As such, on closing of the Share Exchange Transaction, Martino De Ciccio, CEO of Montage, will be appointed as Non-Executive Chairman of the Board of Directors of Sanu. Joint-Technical-Committee: Appointment of Silvia Bottero, EVP Exploration at Montage, to a newly formed joint-technical-committee with Sanu on the Daina and Bantabaye properties. Right of First Refusal: On certain asset-level transactions for Daina and Bantabaye. Furthermore, the ROFR includes any new properties acquired by Sanu subject to the Investor Rights Agreement Threshold. Pursuant to the existing investor rights agreement between AngloGold Ashanti and Sanu, AngloGold Ashanti will be entitled to acquire Sanu Common Shares in connection with the Share Exchange Transaction and Offering on equivalent terms to maintain its pro rata equity interest in Sanu. The Offering includes an allocation of Sanu Common Shares to AngloGold Ashanti to maintain this pro rata equity interest and in the event AngloGold Ashanti elects not to exercise its right, the allocation will be distributed to other investors. The Share Exchange Transaction and the Offering are expected to close in the coming weeks.

06:41 EST B2Gold continuing to operate at Fekola despite temporary labor action - B2Gold is closely monitoring a strike that began on November 29, 2024, by certain employees at the Company's Fekola Mine in Mali. Under the notice provided to the Company by the Fekola workers union, the strike commenced on November 29, 2024 with a seven day duration ending on December 5, 2024. The Company is continuing to operate the Fekola mill at full throughput capacity during this period and still expects to be toward the lower end of its annual production guidance for the Fekola Mine of between 420,000 and 450,000 ounces of gold in 2024. The health, safety and security of B2Gold employees remains the Company's foremost priority. During the seven-day strike period, the Company is continuing to operate critical infrastructure and the mill on a reduced roster, maintaining the expected gold production profile during the period. It is important to note that under Malian legislation, employees are authorized to provide minimum service, and participation in strikes is not compulsory for employees who elect to continue to work. The Company believes that the labour action is primarily in response to the action B2Gold has taken against a small number of Fekola employees that previously engaged in illegal activities detrimental to productivity at the Fekola Mine, including "go slow" actions by the mining employees and an illegal sit in at the Fekola management office in August 2024. During this period, B2Gold urged all Fekola employees to avoid involvement in these illegal activities and, in line with Malian law, Fekola's current union agreements and the B2Gold employee code of conduct, has commenced the disciplinary process for those employees who chose to engage in the illegal activities. B2Gold remains ready and willing to participate in meetings with the Fekola workers union to reach a resolution, and will continue to adhere to legal procedures, respecting the rights of all its employees, inviting the union to engage in a constructive dialogue, and providing the authorities with all requested information. Fekola has well-documented and recognized procedures for raising any form of grievance, as well as established engagement platforms in place with union representatives, to engage on issues concerning B2Gold's employees. B2Gold is committed to the highest standards for integrity and transparency and will continue to focus on safe and sustainable mining at Fekola, which brings great benefits to the workforce, the surrounding communities and the State of Mali. In addition, the Company continues to make progress with the State of Mali on their respective deliverables and implementation of the necessary steps under the Memorandum of Agreement signed in September 2024, including the issuance of the necessary permits to commence exploitation at Fekola Regional. Upon issuance of the exploitation permit for Fekola Regional, mining operations will begin with initial gold production expected to commence in early 2025, with the potential to generate approximately 80,000 to 100,000 ounces of additional gold production on an annualized basis from Fekola Regional sources through the trucking of open pit ore to the Fekola mill. B2Gold continues to have a strong working relationship with the Malian Government.

06:38 EST Bread Financial announces $25M increase to 2024 share repurchase program - Bread Financial announced that its Board of Directors has approved a $25 million increase to its previously-announced 2024 share repurchase program, expanding the authorization from $30 million of common stock to $55 million of common stock through December 31, 2024. The Company had approximately $19 million remaining under its prior share repurchase program as of the date of this release; this increase will bring the total amount of share repurchase authorization to approximately $44 million through December 31, 2024.

06:32 EST Accenture nominates Masahiko Uotani, Jennifer Nason to board of directors - Accenture (ACN) announced that its Board of Directors has nominated Masahiko Uotani and Jennifer Nason for election to the Board following Accenture's annual general meeting of shareholders on February 6, 2025. Uotani-san is the chairman and CEO of Shiseido (SSDOY). Nason is the Global Chair, Investment Banking at J.P. Morgan (JPM). They each will be listed as a director nominee in Accenture's 2024 proxy statement. The preliminary proxy statement is scheduled to be filed with the Securities and Exchange Commission this week. If elected by shareholders at the annual general meeting, Uotani-san will serve on the Finance Committee, and Ms. Nason will serve on the Finance and Compensation, Culture & People Committees. Together with our other nominees, the Board would comprise 11 directors.

06:29 EST IHS Towers signs agreement to sell Kuwait operations to Zain Group - IHS Holding has signed a definitive agreement to sell IHS Towers' 70% interest in IHS Kuwait including its approximate 1,675 sites and an additional approximately 700 sites managed in Kuwait to Zain Group. The transaction is subject to customary closing conditions, including government and regulatory approvals, and is expected to close in the first half of 2025. The terms of the transaction reflect an enterprise value of $230 million for the IHS Kuwait portfolio, implying a transaction multiple of 14.2x based on an estimated IHS Kuwait Adjusted EBITDA after leases. This represents a significant premium compared to the current valuation multiple of the IHS Towers group. Entering into this agreement is part of IHS Towers' ongoing strategic review targeted at shareholder value-creation options. As previously indicated, the proceeds will primarily be utilized to reduce company debt.

06:27 EST IREN increases capacity by 33% to 28 EH/s - IREN has increased its installed self-mining capacity by 33% to 28 EH/s. 31 EH/s expansion update: IREN has increased its installed capacity from 21 EH/s to 28 EH/s following the energization of its Childress Phase 3 substation. Childress Phase 3 construction is near complete and IREN expects to achieve 31 EH/s of installed capacity this month. Miner inventory: sufficient inventory on-site to achieve 31 EH/s: Construction:4 data center buildings complete, energized and hashing; 2 data center buildings remaining, finalization of internal fit-out and progressive completion expected this month IREN's continued delivery against its 31 EH/s expansion target, best-in-class fleet efficiency and low electricity costs positions the business as a large scale, low-cost producer with an all-in cash cost per Bitcoin of ~$29k. Accelerating expansion to 50 EH/s in H1 2025: IREN continues to invest in accretive growth and is accelerating its growth trajectory to 50 EH/s and 810MW of data centers in H1 2025, underpinned by: Single site expansion at Childress, through Childress Phase 4 & 5 with earthworks and foundation works ongoing; Site teams and processes in place to continue cadence of constructing approximately 50MW of data centers per month; S21 Pro miners previously secured.

06:22 EST Kronos Advanced Technologies announces Cyber Monday savings - KRONOS ADVANCED TECHNOLOGIES announced its Cyber Monday sale running from December 2, 2024. Consumers can enjoy up to 50% off select Kronos' flagship products, including advanced air purifiers and accessories, designed to improve indoor air quality for healthier living. The savings continue throughout December with exclusive weekly deals, ensuring customers can experience clean, purified air while staying within budget this holiday season.

06:19 EST LNG Energy withdraws production, capital guidance issued March 4 - As previously disclosed on October 21, 2024 and November 20, 2024, as a result of unexpected production restrictions at certain wells in the Bullerengue natural gas field, the Company has had to limit natural gas deliveries under certain gas sales agreements dedicated to supplying natural gas demand. Lewis Energy Colombia, a wholly-owned subsidiary of the Company, entered into amendment to certain gas sales agreements to reduce the applicable volumes by 5.0 MMbtu/d for a period of four months with no significant changes to the average natural gas sales price. LEC's attempts to address the production disruptions by way of an extensive workover campaign and drilling initiatives have not resulted in production increases. As a result, on November 22, 2024, LEC issued notice to the applicable regulator in Colombia regarding a restriction in the natural gas deliveries under certain supply contracts. The Company expects LEC to issue a notice of force majeure to its gas off-takers in Colombia setting out the technical basis for delivering less natural gas volumes than as set out in the gas sales agreements. LEC continues to receive the proceeds from the natural gas sales and has notified its senior lenders of the foregoing notice

06:14 EST Digihost produces 37 bitcoin in November - The Company held cash, BTC and cash deposits of approximately $10.0 million as of November 30, 2024, which represents a roughly 11% MoM increase over the previous month. Between self-mining and hosting agreements, miners at the Company's facilities produced approximately 37 BTC during the month of November. The Company invested approximately $0.4 million in November in capital expenditures, mining infrastructure support equipment, and deposits, bringing year-to-date CAPEX deployment to a total of nearly $5 million. This significant investment underscores Digihost's commitment to long-term growth while maintaining a disciplined approach to capital allocation, prioritizing self-funding to minimize equity dilution for shareholders wherever possible. Operations Update: Presently, Digihost operates with approximately 100MW of available power across its three sites and has access to an additional 300MW of allocated power for future development. One of the Company's flagship plants was temporarily taken offline earlier in the quarter for scheduled multi-year maintenance and is expected to resume operations by the end of December 2024. The full utilization of this power capacity is projected to drive substantial revenue growth beginning in Q1, 2025. The Company is currently contracted with a leading multi-billion dollar global engineering and consulting firm to initiate the pilot phase of its Tier 3 data center expansion in Alabama. It expects to complete the project by the end of 2025 or early 2026.

06:12 EST Apogee Therapeutics plans to take combination approach to AD - Apogee plans to take a combination approach to AD by targeting Types 1-3 inflammation potentially offering JAK-like inhibition without their associated safety concerns. This approach offers the potential for improved clinical responses over monotherapies and best-in-class dosing. APG990 is a novel, SQ half-life extended mAb targeting OX40L, initially being developed for AD. OX40L is located further upstream in the inflammatory pathway than IL-13 and targeting it could have broader impact on the inflammatory cascade by inhibiting Type 1, Type 2 and Type 3 pathways. Apogee is evaluating APG990 in a Phase 1 healthy volunteer trial to establish safety, tolerability and PK profile, which would enable combination with APG777. The APG777 + APG990 coformulation has been shown to retain stability, injectability, and convenience of individual components. In preclinical studies it has demonstrated broad inhibition of Type 1, Type 2 and Type 3 inflammation with potential for better tolerability than JAK inhibitors. Pending APG990's Phase 1 results expected in the first half of 2025, Apogee plans to initiate its first combination trial in 2025 - a Phase 1b trial designed to evaluate the safety, PK, PD and efficacy of the combination of APG777 and APG990 against DUPIXENT in ~50-75 patients with moderate-to-severe AD with readout expected in second half of 2026. Apogee plans to take a combination approach to the treatment of asthma and COPD, leveraging mechanisms that address both central and local drivers of respiratory diseases, potentially enabling enhanced efficacy and extended dosing regimens. APG333 is a novel, SQ extended half-life mAb targeting TSLP, a key driver of Type 2 and Type 3 inflammation in eosinophilic and non-eosinophilic conditions. A Phase 1 trial in healthy volunteers is planned to commence by the end of 2024, with data expected in the second half of 2025. In preclinical studies, the combination of APG777 + APG333 has been shown to drive broader and deeper inhibition of inflammation centrally with deeper impact on local airway responses compared to approved or in-development biologics, with the potential for a significantly less frequent dosing schedule. Apogee plans to evaluate APG777 and APG333 monotherapies in respective Phase 1b trials in patients with asthma in 2025 to support advancement into future combination trials in asthma and COPD.

06:05 EST Redwire expands European operations, opens office in Warsaw - Redwire Corporation announced the opening of a regional office in Warsaw, expanding the company's European operations to deliver space solutions to a global customer base. Redwire's Poland office will provide specification and design as well as assembly, integration, and testing support for the company's International Berthing and Docking Mechanism. Redwire's IBDM technology will enable autonomous spacecraft docking for the Gateway lunar space station's International Habitat, and iterations of this system could also support other elements of the Gateway as well as low Earth orbit spacecraft and commercial space stations. Additionally, Redwire will partner with Polish universities, medical research institutions, and pharmaceutical companies to leverage the company's trailblazing microgravity capabilities on the International Space Station. With a key objective to recruit local talent, Redwire has hired Marcin Dobrowolski as General Manager of the Polish office. Dobrowolski brings more than a decade of experience in the aerospace industry, with a proven track record of leadership and operational excellence. Prior to joining Redwire, Dobrowolski held leadership roles at PIAP Space and Thales Alenia Space. Dobrowolski has a deep expertise in mechanical engineering and space robotics, along with experience leading major projects for commercial and government space programs.

06:03 EST Innovex completes purchase of Downhole Well Solutions - Innovex International has completed the acquisition of the remaining equity ownership of Downhole Well Solutions. Innovex previously made a minority investment in DWS in May 2023 and is pleased to continue its partnership with DWS and its management team. Founded in 2019, DWS is a leading provider of proprietary drilling optimization and friction reduction tools that are rented to operators in multiple US Land markets. DWS' commitment to customer satisfaction and the superior performance of their unique tools have allowed them to quickly establish themselves as one of the premier providers of downhole drilling optimization tools in the US Land market.

05:56 EST Faraday Future establishes local sourcing initiative in Ras Al-Khaimah - Faraday Future announced its commitment to local sourcing for manufacturing equipment in Ras Al-Khaimah, UAE. This strategic initiative aligns with the company's focus on fostering regional partnerships, streamlining logistics, and accelerating delivery timelines for its planned UAE manufacturing operations.

05:43 EST Keysight Technologies provides update on regulatory clearances for Spirent deal - The boards of Spirent Communications (SPMYY) and Keysight Technologies (KEYS) announced that they had reached an agreement on the terms and conditions of a recommended all-cash acquisition of the entire issued and to be issued ordinary share capital of Spirent, to be effected through a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006. On May 22, the relevant resolutions proposed at the court meeting and general meeting of Spirent shareholders relating to the acquisition were duly passed. In connection with satisfying the regulatory conditions set out in the scheme document, Keysight is proposing to divest Spirent's high-speed ethernet and network security business lines. With support and assistance from Spirent, Keysight has commenced a competitive auction process with a view to completing a sale of the divestment business simultaneously with the acquisition becoming effective. Consistent with Keysight's approach to proactively addressing regulatory processes, Keysight has been engaging with the State Administration for Market Regulation of the People's Republic of China. Keysight and Spirent are committed to continued engagement with SAMR to obtain clearance for the acquisition under the Anti-Monopoly Law of the PRC, and accordingly filed the Acquisition for clearance by SAMR on November 25. Keysight confirms that the French Ministry for the Economy, Finance, and Industry has granted a conditional authorization of the acquisition. In addition, Keysight confirms that the Acquisition has been approved by the German Federal Ministry for Economic Affairs and Climate Action and by the UK's Chancellor of the Duchy of Lancaster under the National Security and Investment Act 2021. Accordingly, Conditions 3.4, 3.5 and 3.6 set out in Part A of Part III of the Scheme Document have been satisfied. Completion of the acquisition remains subject to the satisfaction or waiver of the remaining conditions to the Acquisition set out in Part III of the Scheme Document, including the condition relating to sanction of the Scheme by the Court. With support and assistance from Spirent, Keysight remains committed to working quickly to satisfy the conditions to the acquisition, and Keysight continues to expect the scheme to become effective during the first half of Keysight's current fiscal year. The precise timing for closing of the acquisition remains subject to the pending regulatory clearances. The parties continue to keep the timetable under close review and will provide any updates as required.

05:27 EST KKR, Baupost Group announce joint venture to purchase 33 UK Marriott hotels - KKR (KKR) and The Baupost Group announced a joint venture to purchase a portfolio of 33 Marriott (MAR) hotels across the UK from a wholly owned subsidiary of the Abu Dhabi Investment Authority, or ADIA. Amante Capital, KKR's vertically integrated European hospitality platform, will serve as managing partner for the joint venture and the properties will continue as Marriott branded hotels. The portfolio consists of 33 full-service properties branded as Marriott and Delta by Marriott in London and prime regional cities including Edinburgh, Glasgow, Leeds and Liverpool. Amante Capital's experienced team will manage the portfolio on behalf of the joint venture.

05:17 EST Hafnia announces $100M share buyback program - Hafnia announced the board resolution to authorize the management to initiate a share buyback program of up to $100M, from December 2, to January 27, 2025, subject to market conditions. In furtherance of the authorization, the company hereby announces that it has put in place an agreement with Pareto Securities AS and its subsidiary, Pareto Securities, for the repurchase of the company's shares in open market transactions on the OSE and the NYSE. Pareto will make its own trading decisions concerning the timing of the purchases independently of the company. In order to comply with the European Market Abuse Regulation, the company provides the following required information: the company may repurchase up to 18M shares for a total amount of up to $100M during the period from December 2 until no later than January 27, 2025, and the purpose of the repurchase program is to reduce the number of the company's outstanding shares and to provide returns to the company's shareholders.